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Soybean (Glycine max) is one of the most cultivated crops in the world providing 
the population with large amounts of protein and oil. In addition to its nutritional 
composition, soybean also contains biologically active compounds with potential 
health-promoting properties. The presence of these bioactives may be 
responsible for the lower incidence of chronic diseases in populations that 
consume a significant portion of soybeans in their diet. One group of soybean-
derived bioactives are bioactive peptides and proteins including lunasin, 
Bowman-Birk inhibitor (BBI) and Kunitz-type trypsin inhibitor (KTI). The overall 
objective of this research was to develop a method of preparing lunasin-enriched 
material and evaluate the ability of lunasin-enriched material to inhibit activation 
of the inflammasomes in vitro. Lunasin-enriched materials were prepared using 
calcium chloride and pH precipitation methods and compared with two 
commercially-available lunasin-enriched products. The stability of lunasin against 
pepsin-pancreatin hydrolysis was evaluated in these materials and the effect of 
BBI and KTI concentrations were analyzed. Lunasin concentrations ranged from 
8.5 to 71.0 µg [microgram]/g pre-hydrolysis and 4.0 to 13.2 µg/g after hydrolysis. 
In all products tested, lunasin concentration after pepsin-pancreatin hydrolysis 
(PPH) significantly correlated with BBI and KTI concentrations. One lunasin-
enriched preparation was evaluated for its ability to modify activation of the 
inflammasomes in vitro using THP-1 human macrophages. Aberrant activation of 
the inflammasomes is associated with development of human diseases such as 
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cancer, diabetes and inflammatory bowel diseases. The activation of the 
inflammasomes in THP-1 human macrophages was accomplished by priming 
with lipopolysaccharide followed by adenosine triphosphate. Lunasin-enriched 
material was added during the priming step at concentrations ranging from 
0.0625 to 0.25 mg/mL. Addition of lunasin-enriched preparation led to reduction 
of intracellular reactive oxygen species (ROS) which correlated with reduction in 
the amount of pro-inflammatory cytokines interleukin-1β(beta) and interleukin-18. 
These results indicate that ROSs play an integral role in lunasin’s ability to inhibit 
inflammation and inflammasomes’ activation. This research is the first to report 
on the role of Kunitz-type trypsin inhibitor on the stability of lunasin against PPH 
and potential of lunasin-enriched preparations as chemopreventive agent against 
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Soy is commonly consumed throughout the world, especially in Asian 
countries, because it contains high amounts of protein and many essential amino 
acids that are not commonly found in other plants (Michelfelder, 2009).  Soy was 
used as far back as 9000 B.C in China and 7000 B.C in Japan (Lee et al.,, 
2011)as a staple food.  Soybeans are still an important part of Asian cuisine with 
multiple food products produced such as soymilk, soy sauce, tempeh, and tofu 
(Singh et al., 2008).  Soy is used in Asian cultures because it contains large 
amounts of protein so it is a suitable meat substitute for people with vegetarian 
diets. In modern times, soybeans have become the most widely used legume 
because of its use in food and oil production (Singh et al., 2008).  In 2015, the 
United States produced a total of 3.93 billion bushels of soy (USDA National 
Agricultural Statistics Service, 2016), showing its importance as a crop.  Although 
the United States produces large amounts of soy, it is not used in human food 
products as much as it is in Asia.   
In countries that have higher rates of soy consumption (especially Asia), it 
has been shown that there are decreased risks for certain types of diseases such 
as cardiovascular disease, obesity and cancer (Wu et al., 1998). For instance, 
Asian women have reduced risks of breast and other types of cancers compared 
to women in western countries due to their increased intake of soy (Wu et al., 
2008).  This has prompted studies into the composition of soy to understand this 
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observation. The recent data suggest that bioactive compounds in soy are 
responsible for the reduced risks of certain cancers. However, the exact reasons 
of how bioactive compounds have these protective effects is largely unknown. 
 One group of bioactive compounds are peptides which can be either 
naturally occurring or produced by enzymatic hydrolysis and fermentation.  Food-
derived bioactive peptides in addition to their nutritional value exert a 
physiological effect in the body acting as potential metabolism modulators and 
regulatory compounds (Shahidi & Zhong, 2008).  Some of the bioactive peptides 
found in soy include Bowman-Birk Inhibitor (BBI), Kunitz-Trypsin Inhibitor (KTI), 
soymetides, soymorphins, and lunasin (Wang & Gonzalez De Mejia, 2005). 
Previous studies have shown the chemopreventive property of these bioactive 
peptides associated with their anti-inflammatory effects. BBI inhibited 
autoimmune inflammation and neuronal loss in a mouse model of multiple 
sclerosis (Touil et al., 2008) while KTI suppressed lipopolysaccharide-induced 
inflammation by reducing expressions of pro-inflammatory cytokines tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6. In addition, lunasin 
attenuated obesity related inflammation by reducing production of pro-
inflammatory cytokines monocyte chemoattractant protein-1 and IL-1β in a co-
culture model of RAW 264.7 macrophages and 3T3-L1 adipocytes (Hsieh et al., 
2017). 
Cytokines are small secreted proteins released by immune cells in 
response to a variety of stimuli and have diverse effects on the interactions of 
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cells in the body(Tilg et al., 2016). The IL-1 family has been implicated in different 
pathogenesis associated with their pro-inflammatory effects such as Parkinson’s 
disease (Mao et al., 2017), multiple sclerosis (Barclay & Shinohara, 2017) and 
inflammatory bowel diseases (Peyrin-Biroulet, Lémann, 2011; Ruffolo et al., 
2010). The release of IL-1 family of cytokines such as IL-1β and IL-18 is 
controlled by activation of macromolecular protein complex called the 
inflammasomes(Domiciano et al., 2017). Inflammasomes are multiprotein 
complexes that are formed within macrophages after danger-associated 
molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) stimulation which induce the production of IL-1β and IL18 as well as the 
inflammatory caspase family subtypes (Lu & Wu, 2015).  Chronic inflammation 
by overexpression of the inflammasomes and the associated pro-inflammatory 
cytokines have been linked to multiple conditions, such as metabolic disorders 
(atherosclerosis, Type II diabetes) as well as mucosal immune responses that 
can lead to inflammatory bowel syndrome (IBS) (Strowig et al., 2012). 
To date there is a lack of information on how soybean-based products, such 
as lunasin-enriched material, can modify inflammasomes activation.  If soybean-
based products, especially lunasin-enriched materials, can inhibit the 
inflammasome, then this could lead to more studies to determine if lunasin could 
be a viable chemopreventive option in diseases associated with chronic 
inflammation, as well as for other potential uses.  If future studies are able to 
conclude that lunasin and other soy-based products are able to be used as 
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treatments, then a proposal to the FDA to grant this health promoting claim would 
be the next step.  




The overall objectives are to develop a method of preparing lunasin-enriched 
material and evaluate the ability of lunasin-enriched material to inhibit activation 
of the inflammasomes in vitro. 
Central Hypothesis 
Lunasin-enriched material prepared from defatted soybean flour can inhibit 
activation of the inflammasomes by reducing reactive oxygen species. 
Aims 
Aim 1. To develop a method of preparing lunasin-enriched material and 
determine the effect of soybean protease inhibitors in the stability of 
lunasin against pepsin-pancreatin hydrolysis 
Hypothesis: The concentrations of soybean protease inhibitors BBI and KTI will 
correlate to the stability of lunasin against pepsin-pancreatin hydrolysis in 
different lunasin-enriched preparations. 
1.1 To develop a method of producing lunasin-enriched preparations using 
CaCl2 and pH precipitation methods; 
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1.2 To compare the concentrations of lunasin, BBI and KTI among 
lunasin-enriched preparations and two commercially available lunasin-
enriched products; 
1.3 To determine the effect of BBI and KTI on the stability of lunasin 
against pepsin-pancreatin hydrolysis; and 
1.4 To measure the antioxidant activities of lunasin-enriched preparations 
and their pepsin-pancreatin hydrolysis products. 
Aim 2. To evaluate the potential of lunasin-enriched material to modify 
activation of the inflammasomes in THP-1 human macrophages in vitro. 
Hypothesis: Lunasin-enriched material can inhibit activation of the 
inflammasomes in THP-1 human macrophages in vitro 
2.1 To investigate the effect of lunasin-enriched material in the production 
of IL-1β and IL-18 in THP-1 human macrophages primed and activated by 
lipopolysaccharide and adenosine-triphosphate, respectively; 
2.2 To determine the mechanism of  inactivation of the inflammasomes by 
the  lunasin-enriched material in vitro; and 
2.3 To determine the effect of pepsin-pancreatin hydrolysis on the ability 
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Soybeans and soybean proteins 
 
Soybeans (Glycine max) are an important legume because they contain large 
amounts of protein, and they were used for ~68% of global protein meal 
production in 2006 (Krishnan et al., 2009).  Soybeans contain approximately 40% 
protein per seed (USDA National Agricultural Statistics Service, 2016) and the 
majority of these proteins are one of two storage proteins, the 11s glycinin and 7s 
ß-conglycinin families, which make up 40 and 30% of these proteins, respectively 
(Utsumi et al., 2002).  Another study was able to identify 80 unique proteins 
within the glycinin and ß-conglycinin family, falling under four distinct categories 
based on solubility (Natarajan et al., 2006).  The categories are water-soluble 
albumins, salt-soluble globulins, weak acid/base-soluble glutelins, and alcohol-
soluble prolamins (Ferreira et al., 1999).  Other proteins found within soybean 
include γ-conglycinin, lipoxygenase, ß-amylase, basic 7s globulin, agglutinin, and 
2s albumins from the 2s seed storage protein family (El-moneim et al., 2011).  
Proteins are classified under sedimentation coefficients, or Svedburg units, such 
as 7s and 11s, which uses the weight and shape of the protein to determine the 
coefficient (Smith, 1988).  Albumins are classified in the globular protein family 
due to their shape, but differ categorically from globulins because they are 
soluble in water (Masuelli, 2013), whereas globulins are soluble with low salt 
concentrations (Sirison et al., 2017). 
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Bioactive proteins and peptides from soybean 
 
Glycinin and ß-conglycinin have been found to contain proteins that induce 
allergic reactions (Holzhauser et al., 2009), but other peptide sections contained 
within both of these proteins have bioactive properties, such as improved glucose 
and lipid metabolism from soymorphins (Yamada et al., 2012), and reduced 
cholesterol absorption from soystatins (Nagaoka et al., 2010).  There are other 
bioactive peptides found in soy that come from sources other than the glycinin 
and ß-conglycinin, such as lunasin from 2s albumins, (Galbas et al., 2013) and 
bioactive proteins such as protease inhibitors (Gillman et al., 2015).   
 
Lunasin. Lunasin is a peptide naturally found in soy and other grains such as 
barley and quinoa (Ren & Zhu, 2017).  Soy is the most commonly used source 
for the extraction of lunasin, because it contains large amounts of protein, 
comprising approximately 41% protein, 90% of which are globulins and the 
remaining 10% are albumins (Singh et al., 2008). Lunasin is a 2S albumin with a 
43 amino acid sequence: 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD (Cruz-
Huerta et al., 2015).  Because there are very small amounts of lunasin in soy, 
compared to other proteins, new methods have been implemented in order to 
increase the yields and purity of lunasin directly extracted from soy.  The newest 
method uses 100 grams of de-fatted soy flour in one liter of an aqueous 30% 
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ethanol solution to extract proteins from the soy flour, and it is then centrifuged 
and the supernatant fluid is precipitated with CaCl2 and further centrifuged before 
being lyophilized (Krishnan & Wang, 2015).   
Several studies have shown the chemopreventive effect of lunasin extracted from 
soybean using different in vitro and in vivo experiments. Oral administration of 
lunasin showed that lunasin was able to spread throughout the body and reach 
areas that are most commonly associated with cancer (i.e. colon, breast, lung), 
meaning that it is possible to reach a target site through oral administration only 
(Hsieh et al., 2010).  Another study showed that lunasin was found in the blood 
plasma of men after ingesting soy (Dia et al., 2009) indicating that lunasin is able 
to be absorbed and transported throughout the body.  In the study that used 
intravenous and intraperitoneal administration, it was shown that lunasin 
administered at 30 mg/kg body weight in mouse xenograft model reduced tumor 
weight of A375 melanoma cell line, with the intravenous injection reducing 35% 
of total weight and the intraperitoneal injection reducing 46% of the total weight 
(Shidal et al., 2016). 
Though oral administration of lunasin is the best route for use as a 
chemopreventive agent, lunasin might become digested and proteolyzed if not 
protected by a protease inhibitor such as the Bowman-Birk protease inhibitor 
(BBI).  If there is no protease inhibitor, then pepsin hydrolyzed up to 97% of the 
lunasin, which was the result when the gastric process was simulated in vitro 
(Cruz-Huerta et al., 2015).  Once the peptide has been absorbed into the blood 
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stream, it will reach the target cells and eventually collect in the liver and kidneys 
(Galbas et al., 2013), but there have been studies that indicate it does not affect 
the functionality of the liver or kidney cells (Al-Rayyan et al., 2014).   
There are many health benefits for lunasin, ranging from anti-cancer(Cruz-Huerta 
et al., 2015), anti-obesity (Liu et al. 2014), prevention from cardiovascular 
disease (Cam & de Mejia, 2012), and anti-inflammatory properties (Dia et al. 
2009). The majority of recent studies have focused on the use of lunasin as an 
anti-tumor and cancer treatment through various means, with the most prominent 
being the arginine-glycine-aspartic acid (RGD) motif found along the 32nd-34th 
amino acids in the sequence (Setrerrahmane et al., 2014).  Peptides that contain 
the RGD motif have been found to suppress inflammation and promote apoptosis 
in different cancer cell lines(Dia & de Mejia, 2010).  RGD motif containing 
peptides are able to cause apoptosis through the activation of pro-caspase-3, a 
protein that contains an aspartate-aspartate-methionine site that binds with the 
RGD, which triggers integrin activation and causes the pro-caspase-3 to activate, 
and induces apoptosis among cells by allowing caspase-3 to penetrate the cell 
walls and activate the enzymatic activity of the protein (Buckley et al., 1999).  
Lunasin is also able to amplify the effects of other treatments such as amplifying 
the amount of Interferon Gamma (IFN-γ) produced by natural killer (NK) cells in 
post-transplant lymphoma patients, where IFN-γ is an interferon used for anti-
tumor immunity by enhancing tumor immunogenicity for antigen presentation, 
producing apoptosis in tumor cells, promoting T helper 1 cell differentiation, and 
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enhancing cytotoxicity of CD8+ cytotoxic T lymphocytes (Chang et al., 2014).  
Once the IFN-γ is able to be produced again, the immune system will be able to 
function on an improved level. In addition, lunasin has been shown to be anti-
inflammatory through the inhibition of production of inflammatory responses 
including nitric oxide, prostaglandins, and cytokines(de Mejia & Dia, 2009). For 
instance, lunasin was able to allergic airway inflammation important in asthma 
therapy and allergy immunotherapy (Yang et al., 2015) and lunasin showed 
potent radical scavenging activities in intestinal CaCo-2 cells indicating its 
promising activity to preserve intestinal mucosal integrity against oxidative 
damage (Garcia-Nebot et al., 2014).  
 
Protease inhibitors. Protease inhibitors are molecules (typically proteins) that 
are able to inhibit proteolytic enzymes.  Because there are so many different 
types of protease inhibitors, they have been broken down into “families” and 
“clans” to help in differentiating them through means such as inhibitory sites and 
proteases inhibited (Rawlings et al., 2004).  Proteases are divided into seven 
different families and are all based on the catalytic residues, the site that either 
binds to a peptide bond or utilizes an acid to hydrolyze the peptide bond (Oda, 
2012).  Six families of proteases use different amino acids as the catalytic triad in 
the active site, with the seventh being a metalloprotease.  The largest protease 
family is the serine protease family, which accounts for approximately one third of 
proteases (Di Cera, 2009).  Two proteases that belong to a subfamily of the 
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serine protease family are chymotrypsin-like which cleaves the hydrophobic 
amino acids, and trypsin like which cleaves after arginine and lysine (Rawlings et 
al. 2016).  Two protease inhibitors found in soy come from two different families, 
the BBI family and the Kunitz-type Trypsin Inhibitor (KTI) family.  The BBI found 
in soy has two binding sites, one for trypsin and one for chymotrypsin.  It is able 
to inhibit chymotrypsin and trypsin by the standard, or Laskowski method. The 
Laskowski method is described as an inhibitor having a specific peptide bond 
corresponding to the protease catalytic site, thus binding with it and at a neutral 
pH does not completely hydrolyze, instead forming an equilibrium between 
hydrolyzed and non-hydrolyzed peptide bonds and stable enzyme-substrate 
complex (Laskowski & Kato, 1980; Rawlings et al., 2016).  BBI is able to inhibit 
one trypsin molecule and one chymotrypsin molecule per molecule of BBI using 
a lysine-leucine peptide bond, with lysine binding to trypsin and leucine binding to 
chymotrypsin (Rawlings et al., 2016). The KTI found in soy has a high affinity for 
trypsin, and is responsible for approximately 76% of the trypsin inhibition (Chen 
et al., 2014).  KTI also uses the Laskowski method, but uses an arginine-
isoleucine peptide bond to strongly bind to trypsin (Wasmuth & Lima, 2016), as 
well as protruding loop that is inserted into the active site of enzymes (Azarkan et 
al., 2011).  Since these protease inhibitors are found in soy, they can be 





Bowman-Birk Inhibitor. The BBI is found within soy and other seeds of 




DKEN(Wasmuth & Lima, 2016).  Each source of BBI contains protease inhibitors 
that can differ slightly (as is the case in horse gram and soy which differs only by 
a few amino acids) or greatly (as is the case of eudicots BBI which are typically 8 
kDa with two proteolytic sites versus monocots BBI is either 8 kDa with one 
proteolytic site, or 16 kDa with two proteolytic sites) (Prakash et al., 1996).  This 
specific family of protease inhibitors are a cysteine-rich group, and characterized 
by a lower molecular weight (8 kDa for soy-based) and large amounts of disulfide 
bonds, 7 of which is present in soybean BBI (Odani et al., 1973).  The purpose of 
a protease inhibitor is to protect against enzymes that proteolyze proteins, and 
BBI protects against the proteolytic enzymes trypsin and chymotrypsin (Odani et 
al., 1973). The trypsin and chymotrypsin inhibitory properties are due to multiple 
disulfide bonds creating two inhibition sites (Werner & Wemmer, 1992).  In soy 
processing, the protease inhibitors found are considered to be disadvantageous 
because protein digestibility could be affected (Lu et al., 2015), stemming from 
the protease inhibitors present within soy products that may not be subject to 
extreme heat or pH change such as soy flour and soy milk.  In previous studies 
protein digestibility of soy was linked to pancreatic enlargement and possible 
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disease (Liener & Hasdai, 1986) and led to BBI being thought of as an 
antinutrient, but this was later proven inaccurate as multiple studies showed that 
in smaller concentrations, BBI could prove beneficial (Armstrong et al., 2000; 
Losso, 2008).  In addition, phase I randomized controlled trials on the safety of 
BBI concentrate showed that the inhibitor concentrate was well tolerated by male 
participants with no apparent toxicity and changes in hematological and 
biochemical markers (Lin et al., 2014). BBI has been linked to chemoprevention 
against different types of cancer such as colorectal cancer (Clemente, Marín-
manzano, Arques, & Domoney, 2013), oral cancer (Armstrong et al., 2013; 
William & Papadimitrakopoulou, 2013) and prostate cancer (Kennedy & Steven 
Wan, 2002; Tang et al., 2009). In addition, BBI showed activity against aphid 
parasitoid Aphidius ervi Haliday (Azzouz et al., 2005) and anti-viral properties 
against human immunodeficiency virus? (Ma et al., 2016).   
 
Kunitz Trypsin Inhibitor. The KTI family of protease inhibitors are larger than 
BBI at around 20 kDa and contain fewer cysteine and disulfide bridges.  KTI 
family comes from different sources, first described from bovine pancreas and 
then from soybeans (Kunitz, 1947).  The soy-based KTI is defined by primarily 
inhibiting serine-based proteases including trypsin by using the standard 
mechanism (Laskowski & Kato, 1980).  In soybean, KTI accounts for 
approximately 74% of trypsin inhibition, and even though its inhibition site is able 
to bind to trypsin and chymotrypsin (Bosterling & Quast, 1981), it does not bind 
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as well to chymotrypsin (Chen et al., 2014), which is why the majority of studies 
done thus far focus on BBI.  Some of the proposed health benefits of KTI include 
the inhibition of HIV reverse transcriptase (Fang, Wong, & Ng, 2010), which 
could prove to be beneficial to HIV patients, and a reduction in inflammation 
caused by elastase by inhibiting the enzyme (Ribeiro, Cunha, Fook, & Sales, 
2010). In addition, soybean KTI showed different mechanisms of 
chemopreventive properties including reduction of TNF-α by inhibiting nuclear 
translocation  of NF-κB (Kobayashi et al., 2005) and suppressing c-JUN N-
terminal kinase signaling (Kobayashi et al., 2005). Anti-cancer properties of KTI 
are associated with its ability to suppress urokinase expression leading to 
reduced invasion and metastasis of cancer cells (Inagaki et al., 2005; Kobayashi 
et al., 2004). 
 
Inflammation and inflammasomes 
 
Inflammation is a result of the innate immune system in response to dangers to 
the host, such as cell injury, infection, and recognition of danger-associated 
molecular pathways (DAMPs) and pathogen-associated molecular pathways 
(PAMPs) (Ferrero-Miliani et al., 2007).  Another name for this immune response 
is acute inflammation, which is defined by pro-inflammatory molecules activating 
the immune response and then switching to anti-inflammatory once the insult is 
no longer a threat (Levy et al., 2001).  If these pro-inflammatory molecules are 
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not switched off and the host system returns to a state of homeostasis, then this 
results in chronic inflammation (Monteiro & Azevedo, 2010).   Chronic 
inflammation is a major problem within the host system because homeostasis is 
not available, and this has been linked to metabolic diseases such as obesity and 
type II diabetes (Hsieh et al., 2017), as well as neurodegenerative diseases such 
as Parkinson’s and Alzheimer’s (Mao et al., 2017).  One of the leading causes of 
chronic inflammation is the inflammation cascade associated with sterile 
stressors that are released by intracellular oligomers called inflammasomes 
(Abais et al., 2015).  The inflammasome is activated through a complex pathway 
that is started with the recognition of a DAMP or PAMP which activates the Toll-
like receptor protein 4 (TLR4), which activates the NF-κB that is responsible for 
the translation of inflammasome associated proteins (Walsh, Muruve, & Power, 
2014), and this portion is known as “priming”.  Once the inflammasome is primed, 
a stimulant such as ROS or ATP is needed to “activate” the inflammasome, 
which converts pro-caspase into caspase-1 through thioredoxin-interacting 
protein (TXNIP) binding to the inflammasome allowing cleavage just before the 
active caspase-1 (Zhou et al., 2010).  Once caspase-1 is activated, it cleaves the 
immature pro-inflammatory cytokines interleukin-1ß and interleukin-18 into their 
active forms, which are then expressed out of the cell and initiate the priming 
step as before, creating a cascade of inflammation in neighboring cells (Tőzsér & 







Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., & Li, P.-L. (2015). Redox regulation 
of NLRP3 inflammasomes: ROS as trigger or effector? Antioxidants & Redox 
Signaling, 22(13), 1111–29. http://doi.org/10.1089/ars.2014.5994 
AL_Rayyan, N., Shidal, C., Yaddanapudi, K., & Keith, D. (2014). No Title. 
Endocrine Reviews. 
Armstrong, W. B., Kennedy, A. R., Wan, X. S., Atiba, J., Mclaren, C. E., & 
Meyskens, F. L. (2000). Single-Dose Administration of Bowman-Birk 
Inhibitor Concentrate in Patients with Oral Leukoplakia Single-Dose 
Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral 
Leukoplakia 1. Cancer Epidemiology, Biomarkers & Prevention, 9(January), 
43–47. 
Armstrong, W. B., Taylor, T. H., Kennedy, A. R., Melrose, R. J., Messadi, D. V., 
Gu, M., … Meyskens, F. L. (2013). Bowman birk inhibitor concentrate and 
oral leukoplakia: A randomized phase IIb trial. Cancer Prevention Research, 
6(5), 410–418. http://doi.org/10.1158/1940-6207.CAPR-13-0004 
Azarkan, M., Martinez-Rodriguez, S., Buts, L., Baeyens-Volant, D., & Garcia-
Pino, A. (2011). The plasticity of the β-trefoil fold constitutes an evolutionary 




Azzouz, H., Cherqui, A., Campan, E. D. M., Rahbé, Y., Duport, G., Jouanin, L., 
… Giordanengo, P. (2005). Effects of plant protease inhibitors, oryzacystatin 
I and soybean Bowman-Birk inhibitor, on the aphid Macrosiphum euphorbiae 
(Homoptera, Aphididae) and its parasitoid Aphelinus abdominalis 
(Hymenoptera, Aphelinidae). Journal of Insect Physiology, 51(1), 75–86. 
http://doi.org/10.1016/j.jinsphys.2004.11.010 
Bosterling, B., & Quast, U. (1981). KINETICS OF THE INTERACTION OF a-
CHYMOTRYPSIN WITH EACH, 657, 58–72. 
Buckley, C. D., Pilling, D., Henriquez, N. V, Parsonage, G., Threlfall, K., Scheel-
Toellner, D., … Salmon, M. (1999). RGD peptides induce apoptosis by direct 
caspase-3 activation. Nature, 397(February), 534–539. 
http://doi.org/10.1038/17409 
Cam, A., & de Mejia, E. G. (2012). RGD-peptide lunasin inhibits Akt-mediated 
NF-κB activation in human macrophages through interaction with the αVβ3 
integrin. Molecular Nutrition & Food Research, 56(10), 1569–81. 
http://doi.org/10.1002/mnfr.201200301 
Chang, H. C., Lewis, D., Tung, C. Y., Han, L., Henriquez, S. M. P., Voiles, L., … 
Robertson, M. J. (2014). Soypeptide lunasin in cytokine immunotherapy for 
lymphoma. Cancer Immunology, Immunotherapy, 63(3), 283–295. 
http://doi.org/10.1007/s00262-013-1513-8 
Chen, Y., Xu, Z., Zhang, C., Kong, X., & Hua, Y. (2014). Heat-induced 
inactivation mechanisms of Kunitz trypsin inhibitor and Bowman-Birk 
21 
 
inhibitor in soymilk processing. Food Chemistry, 154, 108–116. 
http://doi.org/10.1016/j.foodchem.2013.12.092 
Clemente, A., Marín-manzano, M. C., Arques, C., & Domoney, C. (2013). 
Bowman-Birk Inhibitors from Legumes : Utilisation in Disease Prevention and 
Therapy. 
Cruz-Huerta, E., Fernández-Tomé, S., Arques, M. C., Amigo, L., Recio, I., 
Clemente, A., & Hernández-Ledesma, B. (2015). The protective role of the 
Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of 
released peptides on colon cancer growth. Food Funct., 6(8), 2626–2635. 
http://doi.org/10.1039/C5FO00454C 
de Mejia, E. G., & Dia, V. P. (2009). Lunasin and lunasin-like peptides inhibit 
inflammation through suppression of NF-??B pathway in the macrophage. 
Peptides, 30(12), 2388–2398. http://doi.org/10.1016/j.peptides.2009.08.005 
Dia, V. P., & Mejia, E. G. de. (2010). Lunasin promotes apoptosis in human colon 
cancer cells by mitochondrial pathway activation and induction of nuclear 
clusterin expression. Cancer Letters, 295(1), 44–53. 
http://doi.org/10.1016/j.canlet.2010.02.010 
Dia, V. P., Torres, S., De Lumen, B. O., Erdman, J. W., & De Mejia, E. G. (2009). 
Presence of lunasin in plasma of men after soy protein consumption. Journal 
of Agricultural and Food Chemistry, 57(4), 1260–6. 
http://doi.org/10.1021/jf803303k 
Dia, V. P., Wang, W., Oh, V. L., Lumen, B. O. d., & de Mejia, E. G. (2009). 
22 
 
Isolation, purification and characterisation of lunasin from defatted soybean 
flour and in vitro evaluation of its anti-inflammatory activity. Food Chemistry, 
114(1), 108–115. http://doi.org/10.1016/j.foodchem.2008.09.023 
Di Cera, E. (2009). Serine proteases. IUBMB Life, 61(5), 510–515. 
http://doi.org/10.1002/iub.186 
El-moneim, A., Mahmoud, E. A., Aliyu, H., Maluszynski, M., & Nichterlein, K. 
(2011). Effect of gamma radiation on protein profile, protein fraction and 
solubility’s of three oil seeds: Soybean, Peanut and Sesame, 39(2), 187–
204. 
Fang, E. F., Wong, J. H., & Ng, T. B. (2010). Thermostable Kunitz trypsin 
inhibitor with cytokine inducing, antitumor and HIV-1 reverse transcriptase 
inhibitory activities from Korean large black soybeans. Journal of Bioscience 
and Bioengineering, 109(3), 211–217. 
http://doi.org/10.1016/j.jbiosc.2009.08.483 
Ferreira, R. B., Franco, E., & Teixeira, A. R. (1999). Calcium- and magnesium-
dependent aggregation of legume seed storage proteins. Journal of 
Agricultural and Food Chemistry, 47(8), 3009–3015. 
http://doi.org/10.1021/jf981151c 
Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S., & Girardin, S. E. (2007). 
Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1ß 




Galbas, M., Porzucek, F., Woźniak, A., Slomski, R., & Selwet, M. (2013). 
Isolation of low-molecular albumins of 2S fraction from soybean (Glycine 
max (L.) Merrill). Acta Biochimica Polonica, 60(1), 107–110. 
García-Nebot, M. J., Recio, I., & Hernández-Ledesma, B. (2014). Antioxidant 
activity and protective effects of peptide lunasin against oxidative stress in 
intestinal Caco-2 cells. Food and Chemical Toxicology : An International 
Journal Published for the British Industrial Biological Research Association, 
65, 155–61. http://doi.org/10.1016/j.fct.2013.12.021 
Gillman, J. D., Kim, W.-S., & Krishnan, H. B. (2015). Identification of a New 
Soybean Kunitz Trypsin Inhibitor Mutation and Its Effect on Bowman−Birk 
Protease Inhibitor Content in Soybean Seed. Journal of Agricultural and 
Food Chemistry, 63(5), 1352–1359. http://doi.org/10.1021/jf505220p 
Guixing Ren, Yingying Zhu, Z. S. (2017). Detection of lunasin in quinoa 
(Chenopodium quinoa, Willd) and the in vitro evaluation of its antioxidant 
and anti-inflammatory activities. Science of Food and Agriculture. 
http://doi.org/10.1002/j 
Holzhauser, T., Wackermann, O., Ballmer-Weber, B. K., Bindslev-Jensen, C., 
Scibilia, J., Perono-Garoffo, L., … Vieths, S. (2009). Soybean (Glycine max) 
allergy in Europe: Gly m 5 (??-conglycinin) and Gly m 6 (glycinin) are 
potential diagnostic markers for severe allergic reactions to soy. Journal of 




Hsieh, C.-C., Chou, M.-J., & Wang, C.-H. (2017). Lunasin attenuates obesity-
related inflammation in RAW264.7 cells and 3T3-L1 adipocytes by inhibiting 
inflammatory cytokine production. PloS One, 12(2), e0171969. 
http://doi.org/10.1371/journal.pone.0171969 
Hsieh, C.-C., Hernández-Ledesma, B., Jeong, H. J., Park, J. H., & de Lumen, B. 
O. (2010). Complementary roles in cancer prevention: protease inhibitor 
makes the cancer preventive peptide lunasin bioavailable. PloS One, 5(1), 
e8890. http://doi.org/10.1371/journal.pone.0008890 
Inagaki, K., Kobayashi, H., Yoshida, R., Kanada, Y., Fukuda, Y., Yagyu, T., … 
Terao, T. (2005). Suppression of urokinase expression and invasion by a 
soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-
dependent signaling pathways. Journal of Biological Chemistry, 280(36), 
31428–31437. http://doi.org/10.1074/jbc.M501406200 
Kennedy, A. R., & Steven Wan, X. (2002). Effects of the Bowman-Birk inhibitor 
on growth, invasion, and clonogenic survival of human prostate epithelial 
cells and prostate cancer cells. Prostate, 50(2), 125–133. 
http://doi.org/10.1002/pros.10041 
Kobayashi, H., Fukuda, Y., Yoshida, R., Kanada, Y., Nishiyama, S., Suzuki, M., 
… Terao, T. (2004). Suppressing effects of dietary supplementation of 
soybean trypsin inhibitor on spontaneous, experimental and peritoneal 
disseminated metastasis in mouse model. International Journal of Cancer, 
112(3), 519–524. http://doi.org/10.1002/ijc.20430 
25 
 
Kobayashi, H., Yoshida, R., Kanada, Y., Fukuda, Y., Yagyu, T., Inagaki, K., … 
Terao, T. (2005). A soybean Kunitz trypsin inhibitor reduces tumor necrosis 
factor-alpha production in ultraviolet-exposed primary human keratinocytes. 
Experimental Dermatology, 14(10), 765–74. http://doi.org/10.1111/j.1600-
0625.2005.00359.x 
Kobayashi, H., Yoshida, R., Kanada, Y., Fukuda, Y., Yagyu, T., Inagaki, K., … 
Terao, T. (2005). Suppression of lipopolysaccharide-induced cytokine 
production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor. 
Journal of Periodontal Research, 40(6), 461–468. 
http://doi.org/10.1111/j.1600-0765.2005.00824.x 
Krishnan, H. B., Oehrle, N. W., & Natarajan, S. S. (2009). A rapid and simple 
procedure for the depletion of abundant storage proteins from legume seeds 
to advance proteome analysis: A case study using Glycine max. Proteomics, 
9(11), 3174–3188. http://doi.org/10.1002/pmic.200800875 
Krishnan, H. B., & Wang, T. T. Y. (2015). An effective and simple procedure to 
isolate abundant quantities of biologically active chemopreventive Lunasin 
Protease Inhibitor Concentrate (LPIC) from soybean. Food Chemistry, 177, 
120–6. http://doi.org/10.1016/j.foodchem.2015.01.006 
Kunitz, M. (1947). Crystalline Soybean Trypsin Inhibitor : Ii. General Properties. 
The Journal of General Physiology, 30(4), 291–310. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/19873496 
Kushner, I. (1998). Semantics, inflammation, cytokines and common sense. 
26 
 
Cytokine and Growth Factor Reviews, 9(3–4), 191–196. 
http://doi.org/10.1016/S1359-6101(98)00016-1 
Laskowski, M. J., & Kato, I. (1980). Protein Inhibitors of Proteinases. Ann. Rev. 
Biochem., 49, 593–626. 
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001). Lipid 
mediator class switching during acute inflammation: signals in resolution. 
Nature Immunology, 2(7), 612–619. http://doi.org/10.1038/89759 
Liener, I. E., & Hasdai, A. (1986). Studies with Mice, 189–197. 
Lin, L. L., Mick, R., Ware, J., Metz, J., Lustig, R., Vapiwala, N., … Kennedy, A. R. 
(2014). Phase I randomized double-blind placebo-controlled single-dose 
safety studies of Bowman-Birk inhibitor concentrate. Oncology Letters, 7(4), 
1151–1158. http://doi.org/10.3892/ol.2014.1855 
Liu, J., Jia, S.-H., Kirberger, M., & Chen, N. (2014). Lunasin as a promising 
health-beneficial peptide. European Review for Medical and 
Pharmacological Sciences, 18(14), 2070–2075. 
Losso, J. N. (2008). The biochemical and functional food properties of the 
bowman-birk inhibitor. Critical Reviews in Food Science and Nutrition, 48(1), 
94–118. http://doi.org/10.1080/10408390601177589 
Lu, L., Zhao, L., Zhang, C., Kong, X., Hua, Y., & Chen, Y. (2015). Comparative 
effects of ohmic, induction cooker, and electric stove heating on soymilk 




Ma, T.-C., Zhou, R.-H., Wang, X., Li, J.-L., Sang, M., Zhou, L., … Wang, X. 
(2016). Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV 
Replication in Macrophages. Scientific Reports, 6(October), 34752. 
http://doi.org/10.1038/srep34752 
Mao, Z., Liu, C., Ji, S., Yang, Q., Ye, H., Han, H., & Xue, Z. (2017). The NLRP3 
Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in 
Rats. Neurochemical Research, 0(0), 0. http://doi.org/10.1007/s11064-017-
2185-0 
Masuelli, M. A. (2013). Study of bovine serum albumin solubility in aqueous 
solutions by intrinsic viscosity measurements. Advances in Physical 
Chemistry, 2013. http://doi.org/10.1155/2013/360239 
Monteiro, R., & Azevedo, I. (2010). Chronic inflammation in obesity and the 
metabolic syndrome. Mediators of Inflammation, 2010(Atp Iii). 
http://doi.org/10.1155/2010/289645 
Nagaoka, S., Nakamura, A., Shibata, H., & Kanamaru, Y. (2010). Soystatin 
(VAWWMY), a novel bile acid-binding peptide, decreased micellar solubility 
and inhibited cholesterol absorption in rats. Bioscience, Biotechnology, and 
Biochemistry, 74(8), 1738–41. http://doi.org/10.1271/bbb.100338 
Natarajan, S. S., Xu, C., Bae, H., Caperna, T. J., & Garrett, W. M. (2006). 
Characterization of storage proteins in wild (Glycine soja) and cultivated 
(Glycine max) soybean seeds using proteomic analysis. Journal of 




Oda, K. (2012). New families of carboxyl peptidases: Serine-carboxyl peptidases 
and glutamic peptidases. Journal of Biochemistry, 151(1), 13–25. 
http://doi.org/10.1093/jb/mvr129 
Odani, S., Ikenaka, T., & Bowman-birk, S. (1973). Studies on Soybean Trypsin 
Inhibitors VIII . Disulfide Bridges in Soybean Bowman-Birk Proteinase 
Inhibitor *, 715, 697–715. 
Prakash, B., Selvaraj, S., Murthy, M. R. N., Sreerama, Y. N., Rajagopal Rao, D., 
& Gowda, L. R. (1996). Analysis of the amino acid sequences of plant 
Bowman-Birk inhibitors. Journal of Molecular Evolution, 42(5), 560–569. 
http://doi.org/10.1007/BF02352286 
Rawlings, N. D., Barrett, A. J., & Finn, R. (2016). Twenty years of the MEROPS 
database of proteolytic enzymes, their substrates and inhibitors. Nucleic 
Acids Research, 44(D1), D343–D350. http://doi.org/10.1093/nar/gkv1118 
Rawlings, N. D., Tolle, D. P., & Barrett, A. J. (2004). Evolutionary families of 
peptidase inhibitors. The Biochemical Journal, 378(Pt 3), 705–716. 
http://doi.org/10.1042/BJ20031825 
Ribeiro, J. K. C., Cunha, D. D. S., Fook, J. M. S. L. L., & Sales, M. P. (2010). 
New properties of the soybean trypsin inhibitor: Inhibition of human 
neutrophil elastase and its effect on acute pulmonary injury. European 




Rubartelli, A., & Lotze, M. T. (2007). Inside, outside, upside down: damage-
associated molecular-pattern molecules (DAMPs) and redox. Trends in 
Immunology, 28(10), 429–436. http://doi.org/10.1016/j.it.2007.08.004 
Setrerrahmane, S., Zhang, Y., Dai, G., Lv, J., & Tan, S. (2014). Efficient 
Production of Native Lunasin with Correct N-terminal Processing by Using 
the pH-Induced Self-Cleavable Ssp DnaB Mini-intein System in Escherichia 
coli. Applied Biochemistry and Biotechnology, 174(2), 612–22. 
http://doi.org/10.1007/s12010-014-1081-1 
Singh, P., Kumar, R., Sabapathy, S. N., & Bawa, A. S. (2008). Functional and 
Edible Uses of Soy Protein Products. Comprehensive Reviews in Food 
Science and Food Safety, 7(1), 14–28. http://doi.org/10.1111/j.1541-
4337.2007.00025.x 
Sirison, J., Matsumiya, K., Samoto, M., Hidaka, H., Kouno, M., & Matsumura, Y. 
(2017). Solubility of soy lipophilic proteins: comparison with other soy protein 
fractions. Bioscience, Biotechnology, and Biochemistry, 81(4), 790–802. 
http://doi.org/10.1080/09168451.2017.1282808 
Smith, C. a. (1988). Estimation of Sedimentation Coefficients and Fric- tional 
Ratios of Globular Proteins. New York, 16(2), 104–106. 
Tang, M., Asamoto, M., Ogawa, K., Naiki-Ito, A., Sato, S., Takahashi, S., & 
Shirai, T. (2009). Induction of apoptosis in the LNCaP human prostate 
carcinoma cell line and prostate adenocarcinomas of SV40T antigen 
transgenic rats by the Bowman-Birk inhibitor. Pathology International, 
30 
 
59(11), 790–796. http://doi.org/10.1111/j.1440-1827.2009.02445.x 
Tőzsér, J., & Benko, S. (2016). Natural Compounds as Regulators of NLRP3 
Inflammasome-Mediated IL-1β Production. Mediators of Inflammation, 2016. 
http://doi.org/10.1155/2016/5460302 
USDA National Agricultural Statistics Service. (2016). Crop Production 2015 
Summary, (January). 
Utsumi, S., Maruyama, N., Satoh, R., & Adachi, M. (2002). Structure-function 
relationships of soybean proteins revealed by using recombinant systems. 
Enzyme and Microbial Technology, 30(3), 284–288. 
http://doi.org/10.1016/S0141-0229(01)00507-5 
Walsh, J. G., Muruve, D. A., & Power, C. (2014). Inflammasomes in the CNS. 
Nature Publishing Group, 15(February), 1–14. 
http://doi.org/10.1038/nrn3638 
Wasmuth, E. V, & Lima, C. D. (2016). UniProt: the universal protein 
knowledgebase. Nucleic Acids Research, 45(November 2016), 1–12. 
http://doi.org/10.1093/nar/gkw1152 
Werner, M. H., & Wemmer, D. E. (1992). Three-dimensional structure of soybean 
trypsin/chymotrypsin Bowman-Birk inhibitor in solution. Biochemistry, 31(4), 
999–1010. http://doi.org/10.1021/bi00119a008 
William, W. N., & Papadimitrakopoulou, V. A. (2013). Optimizing biomarkers and 
endpoints in oral cancer chemoprevention trials. Cancer Prevention 
Research, 6(5), 375–378. http://doi.org/10.1158/1940-6207.CAPR-13-0114 
31 
 
Yamada, Y., Muraki, A., Oie, M., Kanegawa, N., Oda, A., Sawashi, Y., … 
Ohinata, K. (2012). Soymorphin-5, a soy-derived μ-opioid peptide, 
decreases glucose and triglyceride levels through activating adiponectin and 
PPARα systems in diabetic KKAy mice. American Journal of Physiology. 
Endocrinology and Metabolism, 302(4), E433-40. 
http://doi.org/10.1152/ajpendo.00161.2011 
Yang, X., Zhu, J., Tung, C. Y., Gardiner, G., Wang, Q., Chang, H. C., & Zhou, B. 
(2015). Lunasin alleviates allergic airway inflammation while increases 
antigen-specific Tregs. PLoS ONE, 10(2), 1–11. 
http://doi.org/10.1371/journal.pone.0115330 
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010). Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat 




















KUNITZ TRYPSIN INHIBITOR IN ADDITION TO BOWMAN-BIRK 












































 A version of this chapter was originally published by Samuel J. Price, 
Philipus Pangloli, Hari B. Krishnan and Vermont P Dia. Permission is granted by 
ELSEVIER. See Appendix for Copyrights Permission. 
 
 Price SJ, Pangloli P, Krishnan HB, Dia VP. 2016. Kunitz trypsin inhibitor in 
addition to Bowman-Birk inhibitor influence stability of lunasin against pepsin-
pancreatin hydrolysis. Food Research International. 90: 205-215.  
 
SJP performed the experiments, analyzed and interpreted the data and 
wrote the manuscript; PP helped in the experiments and edited the manuscript, 
HBK provided the BBI antibody, generated KTI-mutant soybean and edited the 
manuscript, VPD designed the experiments, helped in the analysis and 
interpretation of data and edited the manuscript. Minor formatting changes were 




Soybean contains several biologically active components and one of this 
belong to the bioactive peptide group. The objectives of this study were to 
produce different lunasin-enriched preparations (LEP) and determine the effect of 
Bowman-Birk inhibitor (BBI) and Kunitz trypsin inhibitor (KTI) concentrations on 
the stability of lunasin against pepsin-pancreatin hydrolysis (PPH). In addition, 
the effect of KTI mutation on lunasin stability against PPH was determined. LEP 
were produced by calcium and pH precipitation methods of 30% aqueous ethanol 
extract from defatted soybean flour. LEP, lunasin-enriched commercially 
available products and KTI control and mutant flours underwent PPH and 
samples were taken after pepsin and pepsin-pancreatin hydrolysis. The 
concentrations of BBI, KTI, and lunasin all decreased after hydrolysis, but they 
had varying results.  BBI concentration ranged from 167.5 to 655.8 µg/g pre-
hydrolysis and 171.5 to 250.1 µg/g after hydrolysis.  KTI concentrations ranged 
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from 0.3 to 122.3 µg/g pre-hydrolysis and 9.0 to 18.7 µg/g after hydrolysis.  
Lunasin concentrations ranged from 8.5 to 71.0 µg/g pre-hydrolysis and 4.0 to 
13.2 µg/g after hydrolysis. In all products tested, lunasin concentration after PPH 
significantly correlated with BBI and KTI concentrations. Mutation in two KTI 
isoforms led to a lower concentration of lunasin after PPH. This is the first report 
on the potential role of KTI in lunasin stability against PPH and must be 
considered in designing lunasin-enriched products that could potentially survive 
digestion after oral ingestion. 





Soybean is the most widely used legume throughout the world being used as a 
source of food, oil and petroleum replacement in plastics and other items (Singh, 
Kumar, Sabapathy & Bawa, 2008). It also contains biologically active 
components with reported health benefits including isoflavones (Messina, 2014), 
saponins (MacDonald et al., 2005) and biologically active peptides (Wang & 
Gonzalez De Mejia, 2005). Biologically active peptides in soybean include the 
naturally occurring Bowman-Birk inhibitor (BBI), Kunitz trypsin inhibitor (KTI) and 
lunasin and peptides that are products of enzymatic hydrolysis and fermentation. 
Lunasin belongs to the 2S soy albumin protein with 43 amino acid residues 
whose biological activity is attributed to the presence of a cell adhesion motif 
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composed of arginine-glycine-aspartic acid residues and a carboxylic acid tail 
composed of 8 aspartic acid residues (Galvez & Lumen, 1999; Lule, Garg, 
Pophely, Hitesh & Tomar, 2015). Lunasin possessed different potential biological 
properties including anti-cancer (Shidal, Al-Rayyan, Yaddanapudi & Davis, 2016; 
Jiang, Pan, Cheng, Li, Liu & Li, 2016;Hsieh, Hernández-Ledesma, Jeong, Park, 
& de Lumen, 2010) anti-inflammatory (Dia, Wang, Oh, de Lumen & de Mejia, 
2009; Cam & de Mejia, 2012; Cruz-Huerta et al., 2015; Hernández-Ledesma, 
Hsieh,& de Lumen, 2009) and immunomodulating properties (Yang et al., 2015; 
Tung et al., 2014). One potential issue on the use of lunasin as a 
chemopreventive and chemotherapeutic agents is its susceptibility to digestion 
as previous studies have shown that up to 97% of the lunasin is digested leading 
to low nanomolar concentrations found in human plasma after ingesting 50 g of 
soy protein (Dia, Torres, de Lumen, Erdman & de Mejia, 2009). One potential 
strategy of decreasing the digestion of intact lunasin is through the action of 
protease inhibitors such as BBI and KTI that are naturally present in soybean. 
BBI is a protease inhibitor that belongs to cystine-rich group characterized by low 
molecular weight (8 kDa for BBI) and large amounts of disulfide bonds (7 for BBI) 
(Odani, Ikenaka & Bowman-Birk, 1973). BBI protects protein digestion by 
inhibiting the activity of trypsin and chymotrypsin (Odani et al., 1973).  Previous 
studies have shown the capability of BBI to protect lunasin from hydrolysis 
brought up by pepsin and pancreatin (Cruz-Huerta et al., 2015; Hsieh et al., 
2010).  In addition, BBI  has possible health benefits such as being a 
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chemopreventative (Clemente, Marín-manzano, Arques & Domoney, 2013) and 
anticarcinogenic agent (Kennedy, 1998). KTI is another protease inhibitor that is 
larger than BBI with molecular weight of approximately 20 kDa and contains less 
disulfide bridges. KTI also demonstrated different biological properties including 
anticancer, anti-HIV1 reverse transcriptase and immunoregulating properties 
(Fang, Wong & Ng, 2010; Inagaki et al., 2005). To date, no one has studied the 
role of KTI on the stability of lunasin against pepsin-pancreatin hydrolysis (PPH).  
The objectives of this study were to produce different lunasin-enriched 
preparations (LEP) and determine the effect of protease inhibitors, Bowman-Birk 
inhibitor and Kunitz trypsin inhibitor, concentrations on the stability of lunasin 
against PPH. 
 
Materials and Methods 
Materials 
 
Prolia defatted soy flour was purchased from Amazon and produced by Cargill 
Mills (Minneapolis, MN).  The commercially-available products (C-LEP) 
(LunaRichX, designated as L and Now, designated as N) were from Reliv 
(Chesterfield, MO). Control and KTI mutant soy flours were obtained as 
previously reported (Gillman, Kim, & Krishnan, 2015). Lunasin polyclonal 
antibody was raised in rabbit using the 15 amino acid corresponding to the C-
terminus of lunasin (ProteinTech Group, Chicago IL), synthetic lunasin standard 
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was synthesized by LifeTein LLC (New Jersey, USA), BBI standard was 
purchased from Sigma-Aldrich (St. Louis, MO) and KTI standard was purchased 
from VWR International (Atlanta, GA). All chemicals were purchased from 
ThermoFisher Scientific and VWR International unless otherwise specified. 
 
Preparation of lunasin-enriched samples and pepsin-pancreatin hydrolysis 
 
Lunasin-enriched samples were prepared following the procedure described 
earlier (Krishnan & Wang, 2015) with slight modifications. Briefly, 100g defatted 
soy flour were mixed with 1-L 30% ethanol solution for 2 h at 20 to 22 °C. After 
centrifugation (8,000 rpm, 4°C) for 30 min, the supernatant was collected and 
calcium precipitation was accomplished by adding CaCl2 to a final concentration 
of 10 mM and stirred for 10 min.  After centrifugation as above the precipitate 
was collected and dissolved in 1 volume distilled water and divided into four 
parts. One part was called Ca LEP and the remaining 3 parts were split into three 
groups and their pH adjusted to 3 (pH 3 LEP), 4 (pH 4 LEP) and 5 (pH 5 LEP).  
After pH adjustment, samples were centrifuged as above and the precipitate was 
collected, resuspended in 10 mL of Tris-buffered saline (TBS) and the pH was 
readjusted to 7.5. The samples were dialyzed in a membrane with 3.5 kDa 
molecular weight cut-off (Spectrum Labs, Rancho Dominguez, CA) frozen and 
lyophilized. Samples were kept at -20 °C until analysis. PPH was performed as 
previously reported (Cruz-Huerta et al., 2015) with some modifications. Briefly, 
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30 mg of lyophilized sample was suspended in 10-mL water and pH adjusted to 
2.0 and pepsin was added at 1:20 enzyme:LEP ratio. Pepsin hydrolysis was 
carried out for 1 h at 37 °C in a shaking water bath after which 5-mL of the 
mixture was taken, heated at 75 °C for 20 min to inactivate pepsin and 
designated as pepsin digests. The pH of the remaining mixture was adjusted to 
7.5 to inactivate pepsin; and pancreatin and bile extract were added at 1:20 
enzyme:LEP ratio and 1:40 bile extract:LEP ratio, respectively. The pancreatin 
hydrolysis was carried out for 1 h at 37 °C in a shaking water bath and pancreatin 
was inactivated by heating at 75 °C for 20 min and called pepsin-pancreatin 
digests. Digests were centrifuged at 20,000 x g for 30 min, supernatants were 
dialyzed, freeze-dried and stored at -20 °C until used. 
 
Soluble protein concentration by Bradford Assay 
 
Ten mg of samples were extracted with 1-mL TBS by vortexing for 90 min at 20 
to 22 °C, followed by centrifugation (20,000 x g, 4 °C) for 30 min and the 
supernatant was used for the analysis based on Bradford (1976) principle. One 
hundred µL of diluted supernatant (1:50) and different concentrations of bovine 
serum albumin standards from 0 to 20 µg/mL were plated in 96-well plate and 
100 µL of Quick StartTM Bradford dye reagent (Bio-Rad Laboratories, Hercules, 
CA) were added. After 5 min of incubation at 20 to 22 °C, the absorbance was 
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read at 630 nm and total soluble proteins were calculated using the generated 
BSA standard curve equation. 
 
Protein profile by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
SDS-PAGE under reducing condition was carried out by loading approximately 
20 µg of protein in 4-20% Mini-Protean TGX gels (Bio-Rad Laboratories, 
Hercules, CA) run at 100 volts for 100 minutes.  Gels were stained with 
approximately 50 mL Bio-safe Coomassie Stain (Bio-Rad Laboratories, Hercules 
Inc.) overnight at 4 °C. Destaining was done by washing with water 3 times for 10 
minutes each or until the background dye was removed. 
 
Western Blot analysis 
 
After the SDS-PAGE was run, gels were equilibrated in blotting buffer (20% 
methanol in SDS-PAGE running buffer) for 15 min.  Proteins were transferred 
into Amersham™Hybond™ 0.45µm PVDF membrane (GE Healthcare, 
Piscataway NJ) at 110 volts for 60 minutes at 4 °C.  After the transfer, the 
membrane was blocked with 5% non-fat dry milk in TBST for 60 min at 20 to 22 
°C.  After washing with TBST three times for 10 minutes each, the membrane 
was incubated in primary antibody against lunasin, BBI (Gillman et al., 2015) and 
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KTI (VWR International, Atlanta GA) at 1:2,000 dilution overnight at 4 °C.  After 
washing, membrane was incubated with anti-rabbit secondary antibody 
(ThermoFisher Scientific) at 1:2000 dilution for 2 h at 20 to 22 °C.  After washing, 
blots were imaged by chemiluminescence using C-Digit blot scanner (Li-Cor 
Biosciences, Lincoln, NE). 
 
Enzyme-Linked Immunosorbant Assay (ELISA) for lunasin, BBI and KTI 
concentrations 
 
One hundred µL of diluted samples (1:2500), lunasin standard, BBI standard and 
KTI standard were plated in triplicate on immuno-96 well plate (BrandTech) and 
incubated for at least 14 h at 4 °C.  Afterwhich, the plate was washed three times 
with 300 µL washing buffer (1L PBS + 5 mL Tween 20, PBST) per well and 
blocked with 300µl of 1% sodium caseinate in PBST for 1 h at 20 to 22 °C.  After 
washing, 50 µL of the primary antibody was added to each well and incubated for 
1 h at 20 to 22 °C.  After incubation and washing, 50 µL of secondary antibody 
solution was added and incubated for 2 h at 20 to 22 °C.  The secondary 
antibody solution was removed and the plate was washed and 100µl of 3,3’,5,5’-
tetramethylbenzidine solution was added to each well and incubated for 30 min 
at 20 to 22 °C in the dark.  After 30 min, the reaction was stopped by adding 
100µl of 2 M H2SO4, and the absorbance was read at 450nm. Lunasin, BBI and 
KTI concentrations were calculated using their respective standard curve. 
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Trypsin Inhibition Assay 
 
Fifty µL of sample (200 µg soluble protein/mL), BBI (200 µg/mL) as positive 
control or assay buffer (Tris buffer, pH 8.2) as blank were plated in 96-well plate 
followed by 50 µL trypsin working solution (160 µg/mL) and incubated for 10 min 
at 20 to 22 °C. After 10 minutes, 50 µl of N-α-benzoyl-D,L-arginine 4-nitroanilide 
trypsin substrate (0.8 mg/mL) was added and incubated for 5 min at 20 to 22 °C. 
The absorbance was read at 405nm. Trypsin inhibition was calculated using the 





The molecular weight profiles of the samples were analyzed by size exclusion 
chromatography on an Agilent 1200 HPLC system (Agilent Technologies, Santa 
Clara, CA) equipped with an autosampler (G1329A), a quaternary pump 
(G1311A), a vacuum degasser (G1322A), a temperature controlled column 
(G1316A) and a diode array detector (G1315D).  The separation was performed 
on a BioSep-SEC-S2000 column (300 X 7.80 mm, Torrance, CA).  The mobile 
phase was 45% acetonitrile in water with 0.1% trifluoroacetic acid at flow rate of 
1.0 ml/min. The injection volume was 20µl with 20 min run time.  The detector 





Oxygen radical antioxidant capacity (ORAC) assay. ORAC assay was done as 
previously described (Mojica, Meyer, Berhow & de Mejia, 2015) briefly 20 µL of 
sample, standard (240 to 4 µM Trolox), and blank were added 96-well plate in 
triplicate followed by 120 µL of fluorescein (70nM final concentration) and 
incubated at 37°C in the dark for 15 minutes. Afterwhich, 60 µL of 2,2’-azobis-(2-
methylpropionamidine) (12mM) was added to each well and the plate was read 
at excitation of 485 nm and emission of 582 nm with a sensitivity of 60 every two 
minutes for 120 minutes. ORAC values were calculated from Trolox standard 
curve and reported as µM Trolox equivalent (TE). 
Nitric Oxide Radical Scavenging Assay. Nitric oxide scavenging assay 
was performed as previously described (Mojica, Meyer, Berhow & de Mejia, 
2015), briefly 50 µL of samples and control were added in triplicate to two 96 well 
plates, and 50 µl of water was added to each well.  One plate received 25 µL of 
100 mM sodium nitroprusside and the other received 25 µL of water, and both 
plates were incubated for 2 hours at 20 to 22 °C in the dark.  100 µL of Griess 
reagent (1:1 1% sulfanillic acid in 5% phosphoric acid, 0.1% N-(1-napthyl)-
ethylenediamine dihydrochloride) was added to each well and incubated for 15 
min at 20 to 22 °C in the dark. Absorbance was read at 550 nm. 
2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity. 
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DPPH radical scavenging was performed as previously described (Dia, Pangloli, 
Jones, McClure & Patel, 2016), briefly 100 µL of samples and control were plated 
in triplicate in a 96 well plate and 100 µL of DPPH solution (2 mg DPPH 
dissolved in 50 mL methanol) was added and incubated at 20 to 22 °C in the 
dark for 30 minutes.  The absorbance was read at 517nm. 
 
KTI mutant flour 
 
The preparation of the KTI mutant flours was done by adding 30 mg of flour per 
10 mL of water and stirred for 90 min at 20 to 22 °C (unhydrolyzed).  The 
hydrolyzed samples contained 30 mg of flour per 10 mL of water and the 
hydrolysis process was performed as described earlier.  After the preparation of 
pre- and post-hydrolysis samples, all samples underwent soluble protein 
concentration, SDS-PAGE, ELISA, trypsin inhibition, size exclusion 




All experiments were performed in at least three independent replicates. Data 
were analyzed using PROC GLM procedure of SAS Version 9.4 and means were 






Protein concentration and protein profile of lunasin-enriched samples 
 
Fig. 3.1a (all figures are listed at the end of this chapter as an appendix) shows 
that C-LEP (N, L) have less soluble protein concentration (43.7 mg/g for N) than 
LEP (108.4 mg/g for pH 4). LEP at pH 5 contained more soluble proteins (58.4 
mg/g) after hydrolysis compared to C-LEP (23.6 mg/g).  Fig. 3.1b shows the 
protein profile of samples before and after hydrolysis; the large molecular weight 
proteins were hydrolyzed indicated by disappearance of the higher weight bands 
after PPH. Fig. 3.1c shows western blot bands for BBI, KTI, and lunasin 
indicating the presence of these proteins in the samples and subsequent 
reduction of signal after PPH. 
 
Concentrations of protease inhibitors, BBI and KTI, are higher in LEP than 
C-LEP 
 
Fig. 3.2a shows the concentration of BBI present in lunasin-enriched products 
before and after hydrolysis. N sample did not contain any BBI while the other 
samples have BBI concentrations ranging from 167.5 to 655.8 µg/g prior to PPH. 
In general, PPH led to reduction in BBI concentrations in all products. Fig. 3.2b 
shows the concentration of KTI present in lunasin-enriched products before and 
45 
 
after PPH. KTI concentrations ranged from 0.32 to 122.3 µg/g before PPH and 
was generally reduced after PPH. Fig. 3.2c shows the capability of different 
products to inhibit the activity of trypsin. N sample did not inhibit the activity of 
trypsin while Ca sample exhibited the highest trypsin inhibition by 50.6 AU/mg 
protein before PPH. After PPH, the capability of these samples to inhibit trypsin 
activity was reduced with Ca sample inhibition at 12.0 AU/mg protein. 
Lunasin concentration after hydrolysis correlates with BBI and KTI 
concentrations in different lunasin-enriched products 
 
Fig. 3.3a shows the concentration of lunasin present in lunasin-enriched 
products before and after hydrolysis. In general, PPH led to the reduction of 
lunasin concentrations. Prior to PPH, lunasin concentrations ranged from 8.5 (N) 
to 71.0 µg/g (pH 3) and  from 4.0 (L) to 13.2 µg/g (pH 3) after hydrolysis. Fig. 
3.3b shows a positive correlation of BBI and KTI concentrations before hydrolysis 
and the percentage residual lunasin concentrations after hydrolysis.  Fig. 3.3c is 
shows the Pearson correlation indicating that the correlations between lunasin 
stability against PPH and BBI and KTI concentrations pre-hydrolysis are highly 







Molecular weight profile of lunasin-enriched products as determined by 
size exclusion chromatography 
 
Fig. 3.4a shows the chromatogram of pH 3 precipitated lunasin-enriched product 
(non-hydrolyzed, pepsin digest, pepsin-pancreatin digest, top to bottom) and Fig. 
3.4b shows table inset of all lunasin-enriched products in the various stages of 
hydrolysis. As indicated, pepsin and pepsin-pancreatin hydrolysis led to a 
reduction in higher molecular weight molecules which is in agreement with the 
protein profile as shown by the SDS-PAGE gels in Fig. 3.1b. For instance, pH 3 
sample molecular weight distribution before PPH was 10.6% <1kda, 3.5% 1-
5kda, 6.0% 5-10kda, 79.8% >10kda.  After PPH, this distribution was changed to 
29.3% <1kda, 18.9% 1-5kda, 15.6% 5-10kda, 36.1% >10kda. 
 
Antioxidant capacity of lunasin-enriched products 
 
Fig. 3.5a shows the ORAC values for LEP and C-LEP with values ranging from 
79.41 to 176.92 µM TE. ORAC values indicated similar capability of samples to 
scavenge oxygen radicals with only L significantly lower than the rest of the 
samples. Fig. 3.5b and 3.5c show antioxidant scavenging potential by Nitric 
Oxide and DPPH, respectively.  In general, lunasin-enriched products were not 




Effect of KTI mutations on the concentrations of bioactive peptides in 
soybean and their stability against pepsin-pancreatin digestion. 
 
Fig. 3.6a shows the protein profile of the control, KTI-1 mutant, and KTI-1,3 
mutant soybean flour before and after PPH. Large molecular weight bands 
disappeared adter PPH. Samples had protein concentrations ranging from 47.2 
(KTI-1,3) to 89.7 mg/g (KTI-1) prior to PPH and  from 16.5 (KTI-1,3) to 21.2 mg/g 
(KTI-1) after hydrolysis (Fig. 3.6b) indicating reduction of protein concentrations 
after PPH. Fig. 3.6c shows BBI concentrations of samples ranging from 46.4 
(KTI-1,3) to 83.6 µg/g (KTI-1) prior to PPH and from 6.2 (KTI-1,3) to 7.2 µg/g 
(KTI-1) after PPH and Fig. 3.6d shows the reduction of KTI in KTI mutant flours 
after hydrolysis with  KTI concentrations ranged from 34.4 (KTI-1,3) to 52.9 µg/g 
(Control) before PPH and from 5.4 (KTI-1) to 8.4 µg/g (Control) after PPH. 
Control, KTI-1, and KTI-1,3 flour contained lunasin 32.5, 35.1, and 32.7 µg/g prior 
to hydrolysis and reduced  to 4.0, 3.3 and 2.8 µg/g, respectively, after hydrolysis 
(Fig. 3.6e). Fig. 3.6f shows trypsin inhibitory capability of the samples ranging 
from 59.1 AU/mg protein (KTI-1) to 64.9 (KTI-1,3) pre-hydrolysis. ORAC values 
ranged from 193.2 µM TE (KTI-1) to 237.0 µM TE (control) as shown in Fig. 
3.6g. After PPH, ORAC values ranged from 145.4 µM TE for control to 147.3 µM 
TE for both of the KTI mutant flours. Fig. 3.7 shows the representative 
chromatograms of KTI-1 mutant flour (unhydrolyzed, pepsin-hydrolyzed and 
pepsin-pancreatin-hydrolyzed; from top to bottom) and the molecular weight 
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distribution for all three sample before and after PPH.  PPH led to reduction in 




Soy is one of the most abundantly produced crops in the U.S., with 3.93B barrels 
being produced stateside (USDA National Agricultural Statistics Service, 2016).  
Previous studies have shown the effects of mutations on the KTI gene within soy 
(Gillman, Kim, & Krishnan, 2015), and the effects of the Bowman-Birk Inhibitor on 
the stability of lunasin (Cruz-Huerta et al., 2015), but to our knowledge our study 
is the first to demonstrate the effect of Kunitz trypsin inhibitor and Bowman-Birk 
inhibitor on the stability of the bioactive peptide lunasin. Lunasin has been shown 
to have multiple health benefits, hence ways of protecting it from the action of 
digestive enzymes is one way to increase the potential biological effects of 
lunasin in the human body. It has been shown in previous studies that lunasin 
can be found in the plasma after eating simple soy products (Dia, Torres, De 
Lumen, Erdman, & De Mejia, 2009), not LEP indicating that consumption of LEP 
with optimum level of protease inhibitor could lead to even higher bioavailability 
of this bioactive peptide. In this study, we used pH precipitation method to 
potentially concentrate lunasin in a previously reported lunasin-enriched 
preparation using calcium precipitation (Krishnan & Wang, 2015). The calcium-
precipitated sample was adjusted to pH 3, 4 and 5 owing to the isoelectric point 
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of  soy protein (~4.5 pH) causing different proteins and different concentrations of 
proteins to precipitate (Gennadios, Brandenburg, Weller, & Testin, 1993). 
Though there is an increase in lunasin concentration in pH 3 sample, the protein 
profile of the three pH precipitated samples did not differ with the protein profile 
of the Ca precipitated sample indicating that there is no increase in lunasin purity. 
We then compared the concentrations of lunasin, BBI and KTI of our LEP with C-
LEP, LunarichX and Now. Results showed that our LEP have higher 
concentrations of these bioactive peptides than C-LEP. Notably, the 
concentrations of BBI and KTI in C-LEP are very low indicating the potential 
effect of processing methods used in production of C-LEP. Previous studies have 
shown that processing could lead to reduction in the concentrations of BBI and 
KTI. Heat-induced protein aggregation led to reduction in KTI and BBI in soymilk 
(Chen, Xu, Zhang, Kong&Hua, 2014) while germination and hydrolysis led to 
modification of these protease inhibitors (Dia, Gomez, Vernaza, Berhow, Chang 
& de Mejia, 2012). As expected, pepsin and pepsin-pancreatin hydrolysis led to 
reduction in the concentration of these bioactive peptides (Fig. 3.2 and 3.3) 
leading to production of low molecular weight peptides as evidenced in SDS-
PAGE profile (Fig. 3.1b) and molecular weight distribution profile as determined 
by size exclusion chromatography (Fig. 3.4) of the samples. The low 
concentrations of KTI and BBI led to lower percentage retention in C-LEP as 
compared to LEP as shown by strong correlations between BBI concentration 
and percentage residual lunasin after pepsin and pepsin-pancreatin hydrolysis 
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and KTI concentration and percentage residual lunasin after pepsin and pepsin-
pancreatin hydrolysis (Fig. 3.3b and 3.3c). Interestingly, in Now (Fig. 3.4b) and 
control, KTI-1 and KTI-1,3 (Fig. 3.7b) samples, the percentage of molecules with 
less than 1 kDa prior to hydrolysis is higher than pepsin digests. This could be 
explained by the starting materials used, Now is a commercially available product 
containing vitamins, minerals and a proprietary blend of different plant extracts 
while control, KTI-1 and KTI-1,3 samples are prepared from whole soybean flour. 
On the other hand, LEP samples were obtained from defatted soybean flour. 
Looking at the molecular weight distribution of molecules with molecular weight 
less than 5 kDa, pepsin digests consistently showed lower percentage as 
compared to pepsin-pancreatin digests, for instance pepsin-hydrolyzed Ca has 
32.6% of less than 5 kDa molecules while pepsin-pancreatin hydrolyzed Ca has 
34.4% of less than 5 kDa molecules. This is true for other LEP samples: 37.2 vs 
48.2% for pH 3; 26.9 vs 46.1% for pH 4; 31.8 vs 36.2% for pH 5, 84.6 vs 93.2% 
for LR and 75.3 vs 91.8% for Now (Fig. 3.1b and Fig. 3.4b). The high 
percentage of these low molecular weight molecules in C-LEP than our LEP 
further shows the importance of BBI and KTI in protecting high molecular weight 
compounds from protease digestion. The increase in the percentage of >10 kDa 
in Now sample after pepsin hydrolysis may be explained by potential crosslinking 
effect as mediated by other ingredients present in Now such as a proprietary 
blend plant extract that may contain certain polyphenols. Procyanidine increased 
the ultimate tensile strength and elongation of gelatin membranes (Chen, Wang 
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& Jiang, 2012) while soy protein isolate-ogaja fruit extract reinforced crosslinking 
of protein networks in the development of gluten-free rice noodle (Lee, Kim, 
Song, Lee, Lee & Yoo, 2016). The pancreatin used in this study is composed of 
trypsin, amylase, lipase, ribonuclease and other proteases as such will be able to 
hydrolyze proteins, fats and starch. Other peptidases with potential hydrolytic 
activity found in human plasma and gastrointestinal tract include kallikrein, 
elastase, collagenase, gelatinase, carboxypeptidase and aminopeptidase. 
Kunitz-type trypsin inhibitor isolated from seeds of Enterolobium contortisiliquum 
was capable of inhibiting human plasma kallikrein and human neutrophil 
elastase, which could potentially explain their capability to inhibit the growth of 
different human cancer cells (Nakahata et al., 2011). On the other hand, HcPI 
inhibitor isolated from Hermodice carunculata was able to inhibit pyroglutamyl 
aminopeptidase II but not the activities of serine, cysteine, aspartic and other 
metallo proteinases (Pascual et al., 2004). These previous studies demonstrated 
the specificity of protease inhibitors which could have potential impact on 
preserving the structure and biological activities of bioactive peptides such as 
lunasin. Previous studies indicated the protective role of BBI on lunasin 
digestibility but to our knowledge this is the first report on the potential protective 
role of KTI on lunasin digestibility. To further investigate the role of KTI in lunasin 
stability against pepsin-pancreatin hydrolysis, two soybean flours with mutations 
in KTI gene was used and compared their behavior with a control soybean flour. 
KTI mutation in KTI-1 isoform did not lead to significantly different residual 
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lunasin concentrations while mutation in KTI-1 and KTI-3 isoforms led to 
significantly lower residual lunasin concentrations than the control soybean flour. 
After pepsin-pancreatin hydrolysis, the percentage residual lunasin in control 
soybean flour is 12.3% which is higher than the percentage residual lunasin in 
KTI-1 mutant flour of 9.4% and KTI-1,3 mutant flour of 8.6%. There results for the 
first time demonstrated the possible role of KTI in the stability of lunasin against 
pepsin-pancreatin hydrolysis. Measurement of the antioxidant activity of the 
samples showed no potential effect of KTI mutations nor pepsin-pancreatin 
hydrolysis on the ORAC values of the samples. 
In summary, we report here the effect of protease inhibitor concentrations on the 
stability of lunasin against pepsin-pancreatin hydrolysis. BBI concentration 
positively correlated with lunasin stability. For the first time, we demonstrated that 
in addition to BBI, KTI also play an important role in protecting lunasin from 
pepsin-pancreatin hydrolysis. These factors must be considered in the production 
of lunasin-enriched dietary supplements in order to ascertain the consumer of the 
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Fig. 3.1. a) Commercially available products have less soluble protein 
concentration than laboratory-prepared lunasin-enriched products. Bars with 
different letter are significantly different from each other (P < 0.05, n = 3). Pepsin-
pancreatin hydrolysis led to a significant reduction in the protein concentration of 
lunasin-enriched preparation as designated by * (P < 0.05) and ** (P < 0.001). b) 
Protein profile of lunasin-enriched preparations as affected by pepsin and pepsin-
pancreatin digestion. Lanes 1 (Ca ppt), 2 (Ca-pepsin hydrolyzed), 3 (Ca-pepsin-
pancreatin hydrolyzed), 4, (pH 3 ppt), 5 (pH 3 ppt-pepsin hydrolyzed), 6 (pH 3 
ppt-pepsin-pancreatin hydrolyzed), 7 (pH 4 ppt), 8 (pH 4 ppt-pepsin hydrolyzed), 
9 (pH 4 ppt-pepsin-pancreatin hydrolyzed) Lanes 10 (pH 5 ppt), 11 (pH 5-pepsin 
hydrolyzed), 12 (pH 5-pepsin-pancreatin hydrolyzed), 13 (LunarichX, L), 14 
(LunarichX, L-pepsin hydrolyzed), 115 (LunarichX, L-pepsin-pancreatin 
hydrolyzed), 16 (Now, N), 17 (Now, N-pepsin hydrolyzed), 18 (Now, N-pepsin-
pancreatin hydrolyzed) and MW: molecular weight marker. c) Western blot profile 
showing the presence of BBI, KTI and lunasin in different lunasin preparations 
and commercially available products as affected by pepsin-pancreatin digestion. 
Lanes 1 (Ca ppt), 2 (Ca-pepsin hydrolyzed), 3 (Ca-pepsin-pancreatin 
hydrolyzed), 4, (pH 3 ppt), 5 (pH 3 ppt-pepsin hydrolyzed), 6 (pH 3 ppt-pepsin-
pancreatin hydrolyzed), 7 (pH 4 ppt), 8 (pH 4 ppt-pepsin hydrolyzed), 9 (pH 4 
ppt-pepsin-pancreatin hydrolyzed).  
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Fig. 3.2. Pepsin-pancreatin hydrolysis affected the concentrations of protease 
inhibitors BBI and KTI as well as trypsin inhibitory activity of different lunasin 
preparations and commercially available products. a) Commercially available 
products have less BBI concentrations than laboratory-prepared lunasin-enriched 
products. Bars with different letter(s) are significantly different from each other (P 
< 0.05, n = 3). BBI was not detected in N product. Pepsin-pancreatin hydrolysis 
led to a significant reduction in the BBI concentrations of lunasin-enriched 
preparation as designated by * (P < 0.001) and ** (P < 0.0001) except for L 
product. b) Commercially available products have less KTI concentrations than 
laboratory-prepared lunasin-enriched products. Bars with different letter(s) are 
significantly different from each other (P < 0.05, n = 3). KTI was not detected in N 
product. Pepsin-pancreatin hydrolysis led to a significant reduction in the KTI 
concentrations of lunasin-enriched preparation as designated by * (P < 0.001) 
and ** (P < 0.0001). c) Commercially available products have less trypsin 
inhibitory capacity than laboratory-prepared lunasin-enriched products. Bars with 
different letter(s) are significantly different from each other (P < 0.05, n = 3). 
Pepsin-pancreatin hydrolysis led to a significant reduction in the trypsin inhibitory 
capacity of lunasin-enriched preparation as designated by * (P < 0.05) and ** (P 
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Fig. 3.3. Lunasin stability against pepsin-pancreatin digestion is affected by the 
concentrations of protease inhibitors BBI and KTI in different lunasin-enriched 
preparations and commercially available products. a) Commercially available 
products have less lunasin concentrations than laboratory-prepared lunasin-
enriched products. Bars with different letter(s) are significantly different from each 
other (P < 0.05, n = 3). Pepsin-pancreatin hydrolysis led to  significant reduction 
in the lunasin concentrations of lunasin-enriched preparation as designated by * 
(P < 0.0001). b) Concentrations of protease inhibitors BBI and KTI positively 
correlated with the percentage residual lunasin concentrations after pepsin and 
pepsin-pancreatin digestions indicating that BBI and KTI have protective effects 
on lunasin against enzymatic digestion. c) An inset table shows the correlation 
coefficient and P-values for lunasin percentage residual concentrations after 



















Fig. 3.3. continued 
a) 
 
















































Pearson correlation coefficient, r, between protease inhibitor concentrations and residual (%) 
lunasin concentrations after pepsin and pepsin-pancreatin digestion.    
      Parameter     
Parameter   LP     LPP   
BBI    0.77     0.76 
    (P < 0.0001)    (P < 0.0001) 
KTI    0.80     0.80 
    (P < 0.0001)    (P < 0.0001)  
BBI: Bowman-Birk inhibitor concentration in unhydrolyzed samples; KTI: Kunitz trypsin 
inhibitor concentration in unhydrolyzed samples; LP: lunasin concentration after pepsin 




Fig. 3.4.  Molecular weight distribution of lunasin enriched samples. a) 
Chromatogram of pH 3 precipitated lunasin-enriched product (non-hydrolyzed, 
pepsin digest, pepsin-pancreatin digest in descending order), and b) Table inset 
of all lunasin-enriched products in the various stages of hydrolysis (sample name 
indicates no hydrolysis, P = Pepsin digest, PP = pepsin-pancreatin digest) which 







































Molecular weight distribution after pepsin and pepsin-pancreatin hydrolysis ofdifferent lunasin-
enriched preparations and commercially available products       
Sample*   Molecular weight range (kDa)      
   < 1  1 – 5  5 – 10  > 10    
CaCl2   9.4  2.9  4.1  83.4 
CaCl2-P  19.8  12.8  21.9  45.3 
CaCl2-PP   19.3  15.1  10.5  55.0    
pH 3   10.6  3.5  6.0  79.8 
pH 3-P   22.1  15.1  18.5  44.2 
pH 3-PP  29.3  18.9  15.6  36.1    
pH 4   13.4  9.5  6.0  70.9 
pH 4-P   19.2  7.7  15.3  57.6 
pH 4-PP  28.6  17.5  0  53.8    
pH 5   12.2  9.5  5.7  72.5 
pH 5-P   18.7  13.1  17.2  50.9 
pH 5-PP  21.3  14.9  9.8  53.7    
LunaRich  42.2  3.2  6.1  48.3 
Lunarich-P  49.8  35.8  11.0  3.3 
LunaRich-PP  65.3  27.9  6.6  0    
Now   87.7  8.2  2.9  0.9  
Now-P   40.8  34.5  12.4  12.1 






Fig. 3.5. Antioxidant activity of lunasin-enriched preparations is associated with 
oxygen radical scavenging but not to nitric oxide and DPPH radicals scavenging. 
a) ORAC values for lunasin-enriched preparations are significantly higher than 
LunaRichX but similar to Now. b) Lunasin-enriched preparations do not possess 
the capability to scavenge NO radicals and c) Lunasin-enriched preparations do 







































































































Fig. 3.6. Effect of KTI mutations on the concentrations of bioactive peptides in 
soybean and their stability against pepsin-pancreatin digestion. a) 
Electrophoresis profile showing degradation of proteins after pepsin and pepsin-
pancreatin digestion Lanes MW: molecular weight marker, 1: control soy flour, 2: 
control after pepsin hydrolysis, 3: control after pepsin-pancreatin hydrolysis, 4: 
KTI-1 mutant soy flour, 5: KTI-1 mutant soy flour after pepsin hydrolysis, 6: KTI-1 
mutant soy flour after pepsin-pancreatin hydrolysis, 7: KTI-1,3 mutant soy flour, 
8: KTI-1,3 mutant soy flour after pepsin hydrolysis, 9: KTI-1,3 mutant soy flour 
after pepsin-pancreatin hydrolysis; b) KTI-1 mutant soy flour has higher soluble 
protein concentration than control flour (#, P = 0.0099) while KTI-1,3 mutant soy 
flour has lower soluble protein concentration than control flour (*, P = 0.0250). 
After pepsin and pepsin-pancreatin hydrolysis, KTI mutation did not affect soluble 
protein concentration; c) BBI concentration of KTI-1 mutant soy flour is 
significantly higher than control soy flour (#, P = 0.0016) while BBI concentration 
of KTI-1,3 mutant soy flour is significantly lower than control soy flour (*, P = 
0.0153). KTI-1,3 mutation led to a significantly lower residual BBI concentration 
than control soy flour after pepsin-pancreatin hydrolysis. d) KTI mutation led to a 
significantly lower KTI concentration in KTI-1 mutant flour (* P = 0.0366) and KTI-
1,3 mutant flour (**, P < 0.0001) than control soy flour. Pepsin and pepsin-
pancreatin hydrolyzates of KTI mutant flours have lower residual KTI 
concentrations that control flour (**, P < 0.0001); e) KTI mutation did not affect 
the concentration of lunasin in unhydrolyzed and pepsin-hydrolyzed soy flour 
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while KTI-1,3 mutation led to a significantly lower residual lunasin concentration 
after pepsin pancreatin hydrolysis than control soy flour (*, P = 0.0474); f) KTI 
mutation did not affect the capability of soy flour to inhibit trypsin activity and G) 
KTI mutation did not affect the antioxidant capacity of soy flour extract as 
measured by ORAC. Pepsin-pancreatin hydrolysis led to significant lower 




















Fig. 3.6. continued 
a)         b)  
  
     MW 1   2    3    4    5   6    7    8    9 
c)         d)  
   
e)         f) 













































































































































Fig. 3.7. Molecular weight distribution of control, KTI-1 mutant and KTI-1,3 
mutant flours as affected by pepsin and pepsin-pancreatin hydrolysis. a) 
Representative chromatograms of KTI-1 mutant flour (unhydrolyzed, pepsin-
hydrolyzed and pepsin-pancreatin-hydrolyzed; from top to bottom) and b) Table 
inset showing the molecular weight distribution for unhydrolyzed, pepsin-








































Retention time (min) 
b)  
Molecular weight distribution after pepsin and pepsin-pancreatin hydrolysis of 
control, KTI-1 mutant and KTI-1,3 mutant soy flours.      
Sample*    Molecular weight range (kDa)    
   < 1  1 – 5  5 – 10   > 10   
Control  50.7   0.1   7.0  42.3 
Control-P  42.7   36.3   19.0  2.1 
Control-PP  61.9   25.5   10.5  2.1 
KTI-1   53.2   0.2   7.6  39.1 
KTI-1-P  42.6   36.6   14.4  6.4 
KTI-1-PP  60.8   26.8   12.4  0 
KTI-1,3  56.8   2.1   7.0  34.1 
KTI-1,3-P  43.6   35.8   20.5  0.1 









LUNASIN-ENRICHED MATERIAL INHIBITS ACTIVATION OF THE 
INFLAMMASOMES IN THP-1 HUMAN MACROPHAGES BY 






Inflammation caused by the NLRP3 inflammasome has been linked to many 
diseases, and multiple pathways to activate the inflammasome have been 
described using different signals including the production of reactive oxygen 
species.Lunasin, a bioactive peptide in soybean, was previously reported to 
inhibit nuclear factor of kappa B-mediated transcription, first step in 
inflammasomes activation. The objective was to determine the ability of lunasin-
enriched preparation (LEP) to inhibit inflammasomes activation in vitro using 
THP-1 human macrophages.  THP-1 human monocytes were differentiated into 
macrophages with cells using phorbol 12-myristate 13-acetatebefore being 
treated with different concentrations of LEP (0.0625 to 0.25 mg/mL) in the 
presence of 1 µg/mL lipopolysaccharide as the priming signal for 6 hours. After 
priming, inflammasomes were activated by adding 5 mMadenosine triphosphate. 
Unhydrolyzedd LEP treatment at 0.25 mg/mL led to inhibition of IL-1β and IL-18 
release in the cell culture supernatant by 52.0 and 49.6%, respectively. In 
addition, LEP treatment inhibited the production of intracellular reactive oxygen 
species (ROS) in THP-1 human macrophages without affecting the expressions 
of NLRP3 and ASC proteins involved in activation of inflammasomes. Pepsin-
pancreatin hydrolysis reduced the ability of LEP to inhibit production of 
intracellular ROS. Our results showed that LEP inhibited activation of 






Inflammation occurs when pattern recognition receptors (PRRs) identify 
exogenous pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) (Abais, Xia, Zhang, Boini, & Li, 2015).  
PAMPs are molecules associated with pathogens and infection, such as 
lipopolysaccharide (LPS), an endotoxin associated with gram-negative bacteria 
(Kulp & Kuehn, 2012).  LPS is recognized by the pattern recognition receptor, 
PRR Toll-Like Receptor 4 (TLR4) which activates nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) (Lu, Yeh, & Ohashi, 2008).  DAMPs 
are molecules that are associated with internal cellular damage and activate NF-
κB (Rubartelli & Lotze, 2007).  A novel theory is that mitochondrial reactive 
oxygen species (ROSs) are produced after the cell has been damaged, and 
induce the priming step of inflammasome activation in which NF-κB transcribes 
the components of the inflammasome, particularly pro-interleukin-1ß (pro-IL-1ß) 
and nucleotide-binding oligomerization domain, leucine rich repeat and pyrin 
domain containing 3 (NLRP3) (Tőzsér & Benko, 2016).  After priming, DAMPs 
and PAMPs cause NLRP3 oligomerization and bind to apoptosis-associated 
speck-like protein containing a caspase-recruitment domain (ASC) which then 
binds to pro-cysteine-aspartic protease-1 (pro-caspase-1), resulting in a large 
oligomer that activates caspase-1 (Tschopp & Schroder, 2010).  Once activated, 
caspase-1 is able to cleave pro-IL-1ß, resulting in the mature IL-1ß which is then 
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expressed out of the cell and acts as a cytokine, resulting in a cascade of 
inflammation (Haneklaus, O’Neill, & Coll, 2013).  Inflammasomes are associated 
with chronic inflammation which can damage the integrity of cells, resulting in 
diseases such as Alzheimer’s, type II diabetes, atherosclerosis, and gout (Abais 
et al., 2015). 
Lunasin is a bioactive peptide found in soy with a unique amino acid 
sequence that includes an arginine-glycine-aspartic acid motif(Lule, Garg, 
Pophaly, Hitesh, & Tomar, 2015).  Previous studies have shown the potential of 
lunasin to act as a chemopreventive agent (Dia & Mejia, 2010; Shidal, Al-
Rayyan, Yaddanapudi, & Davis, 2016;Cruz-Huerta et al., 2015; Hernández-
Ledesma, Hsieh, & de Lumen, 2009; Hsieh, Chou, & Wang, 2017). This 
chemopreventive property of lunasin may be associated with its ability to inhibit 
inflammation through NF-κB signaling in THP-1 human macrophages (Cam and 
de Mejia, 2012), the priming step in inflammasome activation. This led us to ask 
if lunasin-enriched preparation (LEP) can inhibit inflammasomes activation in 
THP-1 human macrophages. 
 This study aims to evaluate the ability of LEP to inhibit activation of the 
inflammasomes in vitro and determine the potential mechanism of action. In 










Prolia defatted soy flour was purchased from Amazon and produced by Cargill 
Mills (Minneapolis, MN).  THP-1 human leukemia monocyte cells were obtained 
from American Type Culture Collection (Manassas, VA).Roswell Park Memorial 
Institute-1640 (RPMI) growth media was obtained from Corning Inc. (Conring, 
NY). Fetal Bovine Serum (FBS) was obtained from Life Tech (Carlsbad, CA).  
LPS and Phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma-
Aldrich Corp. (St. Louis, MO). Primary antibodies (ASC 10500-1-AP, Beta-actin 
60008-1-I9, caspase-1 22915-1-AP, and IL-1ß 60136-1-Ig) were obtained from 
Proteintech Group Inc. (Chicago, IL).  Secondary antibodies (Goat anti-mouse 
926-80010, goat anti-rabbit 926-80011) were obtained from Li-Cor Biosciences 
Inc.(Lincoln, NE).  ELISA kit for IL-1ß was obtained from BioLegend Inc. (San 
Diego, CA) and IL-18 kit was purchaseded from Research and Diagnostics 
Systems Inc.(Minneapolis, MN). 
LEP preparation was done by stirring 100g defatted soy flour with 1-L 30% 
ethanol solution for 2 h at 20 to 22 °C, then followed by centrifugation (8000 rpm, 
4 °C) for 30 min. The supernatant was then collected and calcium precipitation 
was accomplished by adding CaCl2 to a final concentration of 10 mM and stirred 
for 10 min. After centrifugation as above, the precipitate was collected and 
dissolved in 1 volume distilled water before dialysis with a 3.5kDa molecular 
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weight cutoff membrane (Spectrum Labs, Rancho Dominguez, CA) then frozen 
and lyophilized.  
 
Protein profile by size-exclusion chromatography and high-performance 
liquid chromatography 
 
The molecular weight profile of the sample was analyzed by size exclusion 
chromatography on an Agilent 1200 HPLC system (Agilent Technologies, Santa 
Clara, CA) equipped with an autosampler (G1329A), a quaternary pump 
(G1311A), a vacuum degasser (G1322A), a temperature controlled column 
(G1316A) and a diode array detector (G1315D). The separation was performed 
on a BioSep-SEC-S2000 column (300 × 7.80 mm, Torrance, CA). The mobile 
phase used was 45% acetonitrile in water with 0.1% trifluoroacetic acid at flow 
rate of 1.0 mL/min. The injection volume was 20 μL with 20 min run time. The 
detector was set at 214 nm and the analysis was performed at ambient 
temperature 
 
Cell culture and treatment 
 
THP-1 human leukemia monocyte cells were cultured using RPMI 1640 that 
contained 10% FBS, 1% penicillin-streptomycin, 1% sodium pyruvate, 10mM 
HEPES, and 50µM ß-mercaptoethanol.  After the cells were allowed to 
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proliferate, they were treated with 162nM of PMA to allow differentiation into 
macrophage-like cells as previously described (Montoya-Rodríguez, de Mejía, 
Dia, Reyes-Moreno, & Milán-Carrillo, 2014) with slight modification.  Cells were 
seeded into 6 and 12-well plates at a concentration of 500,000 cells/mL and 
differentiation occurred for 24h at 37°C in a 5% CO2/95% air incubator.  After 
differentiation, the cells were treated with 0.25, 0.125, and 0.0625mg/ml LEP in 
the presence of 1 µg/mL LPS for 6 h.  After 6 h, ATP was added at 5 mM to treat 
cells for another hour. Negative control cells were left in plain RPMI. The 
concentration of LEP did not affect viability of THP-1 cells as determined by MTS 
assay. 
 
Whole cell lysates preparation and cell culture supernatant collection 
 
After the cells were treated, the plates were placed on ice while the supernatant 
was collected in microcentrifuge tubes, then the cells were washed with ice cold 
PBS twice to remove cell debris.  After washing, 100 µL of RIPA lysis buffer 
(protease inhibitor cocktail to RIPA 1:100) was added to each well and incubated 
for 5min at 4°C.  Cells were harvested using cell scrapers and added to pre-
chilled microfuge tubes, then vortexed for 5min at 4°C before being centrifuged at 
14,000 x g for 10min at 4°C.  The supernatant was then collected and the pellet 
discarded.  Bradford protein analysis assay was performed to determine protein 
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concentration using bovine serum albumin as the standard, before denaturation 
with Laemmli buffer containing 5% ß-mercaptoethanol and boiling for 5 minutes. 
 
 
Western blot for NLRP3 and ASC 
 
SDS-PAGE under reducing condition was carried out by loading approximately 
10 μg of protein in 4–20% Mini-Protean TGX gels (Bio-Rad Laboratories, 
Hercules, CA).  After the SDS-PAGE was runat 200 V for 35 min, gels were 
equilibrated in blotting buffer (20% methanol in SDS-PAGE running buffer) for 
15 min. Proteins were transferred into Amersham™Hybond™ 0.45 μm 
polyvinylidene fluoride membrane (GE Healthcare, Piscataway NJ) at 110 V for 
60 min at 4 °C. After the transfer, the membrane was blocked with 5% non-fat dry 
milk in TBST for 60 min at 20 to 22 °C. After washing with TBST three times for 
10 min each, the membrane was incubated in primary antibody againstNLRP3 
(NOD-like receptor family pyrin domain containing 3), ASC (Apoptosis-associated 
speck-like protein containing a CARD) at a 1:2000 dilution, and Beta-actin at a 
1:5000 (Proteintech Group, Chicago IL) for 3 h at 20 to 22 °C.  After incubation, 
the membrane was washed as described previously, and incubated with 
secondary antibodies at a 1:1000 for 1.5 h at 20 to 22 °C(goat anti-rabbit for ASC 
and NLRP3, and goat anti-mouse for Beta-actin). After washing as above, 300µl 
of a 1:1 mixture of WesternSure Premium stable peroxide and luminol enhancer 
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was added and the membrane was imaged by chemiluminescence using C-Digit 
blot scanner (Li-Cor Biosciences, Lincoln, NE).  Membranes were stripped for 
reprobing with β-actin using a mild stripping buffer twice for 10 min, followed by a 
wash with PBS twice for 10 min, then washed with TBST twice for 5 min before 
being blocked as described previously.   
 
Measurement of intracellular reactive oxygen species 
 
Fluorescence microscopy. THP-1 cells were treated as described previously.  
After the treatment, the plate was placed on ice and the supernatant was 
removed by pipetting before the cells were washed with 500 µL ice-cold PBS 
twice.  After washing, 1 mL of 10 µM 2’7’-dichlorofluoroscein diacetate was 
added to each well before being incubated at 37°C for 10 min in a 5% CO2 
incubator.  After incubation, the dye was removed and the cells were washed 
with PBS twice before pictures were taken using a 20x magnification green 
fluorescent protein (GFP) channel on an Evos microscope (Thermo Fisher 
Scientific, Waltham MA).  
Fluorescence spectrophotometry. THP-1 cells were treated and harvested as 
described previously, and after the wash step, 200 µL of a 0.25% trypsin in 1mM 
ethylenediaminetetraacetic acid was added to each well and incubated for 5 min 
to detach cells from the plate.  After incubation, 800 µL of complete RPMI was 
added to inactivate trypsin, and the media was collected and centrifuged at 500 x 
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g for 5 min.  The supernatant was then discarded and the pellet was re-
suspended in 500 µL of PBS containing 10 µM 2’7’-dichlorofluoroscein diacetate 
and incubated for 30 min at 37°C in a 5% CO2 incubator before being vortexed 
and 200 µL of the suspension was plated in duplicate on a 96-well plate and read 
with a fluorescence intensity at 485 nm/528 nm. 
Flow cytometry. THP-1 cells were treated the same as described in fluorescence 
spectrophotometry, except the number of cells with green fluorescence and 
intensity were measured using an FL 1 channel (FITC) on a MACSQuant flow 
cytometer from (Miltenyi Biotec Inc., Bergisch Gladbach, Germany). 
 
Measurement of released interleukin-1ß and interleukin-18 in the cell 
culture supernatant by enzyme-linked immunosorbent assay (ELISA) 
 
Interleukin-1ß. Measurement ofextracellular IL-1ß that was released into the 
supernatant was performed by ELISA, using a Human IL-1ß ELISA MAX™ 
Deluxe Set obtained from BioLegend Inc. (San Diego, CA).  One hundred µL of 
detection antibody was added to an uncoated 96-well ELISA plate and incubated 
for at least 14 h at 4°C.  After incubation, the plate was washed with 300 µL of 
washing buffer (0.5% Tween 20 in PBS) four times, then blocked by adding 200 
µL of assay diluent A and incubated for 1 h on an orbital shaker at approximately 
50rpm at 20 to 22 °C.  After blocking, the plate was washed as previously 
described, and 50 µL of Assay Buffer D and 50 µL of diluted samples (1:50) and 
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standard were added in duplicate and incubated for 2 h under the same 
conditions.  After incubation with the samples, the plate was washed again and 
100 µL of diluted Detection Antibody were added to each well and incubated for 1 
h under the same conditions.  After washing, 100 µL of diluted avidin-horseradish 
peroxidase solution was added to each well and incubated for 30 min under the 
same conditions.  Then, the plate was washed 5 times with 30 s of soaking 
between each wash, and 100 µL of substrate solution F was added and 
incubated in the dark for 20 min before adding 100 µL of 2 N H2SO4 to stop the 
reaction. The plate was immediately read at 450 nm using a Cambrex microplate 
reader (BioTek Inc, Winooski, VT). 
Interleukin-18. Measurement of interleukin-18 that was released into the 
supernatant was performed using an ELISA kit obtained from R&D Systems 
(Research and Diagnostics Systems Inc., Minneapolis MN) and slight 
modifications to the IL-18 method: the detection antibody was incubated for 2 h, 




All experiments were performed in at least three independent replicates. Data 
were analyzed using PROC GLM procedure of SAS Version 9.4 (SAS Institute, 
Car, NC) and means were separated using Tukey posthoc test and significance 





Characterization of lunasin-enriched preparation 
 
Fig. 4.1a (all figures are listed in the appendix of this chapter) shows the size 
exclusion chromatography profile of LEP before and after pepsin-pancreatin 
hydrolysis. As shown, pepsin-pancreatin hydrolysis led to digestion of high 
molecular weight compounds to low molecular weight molecules. In addition, 
HPLC analysis (Fig. 4.1b) showed that pepsin-pancreatin hydrolysis led to 
reduction of intact lunasin in LEP. 
Effect of lunasin-enriched preparation on secretion of IL-1β and IL-18 in cell 
culture supernatant 
 
Fig. 4.2a shows the effect of different treatment regimens on the production of IL-
1ß by THP-1 human macrophages. Compared to untreated cells producing a 
small amount of IL-1ß, addition of LPS led to a significant increase in the amount 
of IL-1ß produced. Addition of ATP led to further increase in IL-1ß indicating 
activation of inflammasome.  LEP treatment led to a significant reduction of IL-1ß 
secretion indicating the ability of LEP to inhibit inflammasome activation. 
Unhydrolyzed LEP at 0.25 mg/mL reduced IL-1ß secretion by 52.0% while 
hydrolyzed LEP at the same concentration reduced IL-1ß secretion by 75.9%. 
Fig. 4.2b shows the effect of different treatments on IL-18 production by THP-1 
human macrophages.At all LEP concentrations, unhydrolyzed LEP significantly 
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reduced IL-18 production ranging from 49.7% to 63.6%. On the other hand, only 
0.25 mg/mL LEP-hydrolyzed treatment led to significant decrease in IL-18 
production by 49.6%. 
 
Effect of lunasin-enriched preparation did not affect the expression of 
NLRP3 and ASC proteins involve in inflammasomes in THP-1 human 
macrophages 
 
Fig. 4.3 indicates that LEP treatment, whether unhydrolyzed or hydrolyzed, did 
not affect expression of NLRP3 and ASC proteins involve in inflammasome. 
 
Effect of lunasin-enriched preparation on production of intracellular 
reactive oxygen species in THP-1 human macrophages 
 
THP-1 macrophage like cells after treatment with LEP, LPS, and LPS + ATP 
were incubated with 2’7’-dichlorofluoroscein diacetate, a non-fluorescent dye that 
fluoresces after oxidation caused by ROSs(Owusu-Ansah, Yavari, & Banerjee, 
2008).  Images show increased fluorescence with LPS and LPS + ATP (Fig. 4.4) 
compared to the control, as well as a significant decrease in fluorescence with 
increased concentrations ofunhydrolyzed LEP. On the other hand, slight 
reduction was observed in cells treated with hydrolyzed LEP. To confirm this 
observation, quantitative fluorescent spectrophotometry and flow cytometry were 
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conducted.At all concentrations used, unhydrolyzed LEP led to a significant 
reduction in mean fluorescence intensity as compared to LPS + ATP-treated cells 
(Fig. 4.5a). At 0.25 mg/mL unhydrolyzed LEP, the mean fluorescence intensity 
was reduced from 723.25 (LPS + ATP) to 362.25 (LPS + ATP + 0.25 mg/mL 
unhydrolyzed LEP) which is equivalent to 49.9%.  On the other hand, hydrolyzed 
LEP significantly reduced the production of intracellular ROS only at the highest 
concentration used (0.25 mg/mL), by 30.9%. Fig. 4.5b shows the mean and 
median fluorescence intensity from flow cytometry compared with the percentage 
of stained cells in both unhydrolyzed and hydrolyzed LEP treatments, as well as 
the histogram plots of the observed FITC-A fluorescence of the different 
treatments.  In both treatments, addition of LPS alone and LPS + ATP led to a 
significant increase in the percentage of cells stained as well as mean and 
median fluorescence intensities. In THP-1 cells treated with unhydrolyzed LEP, 
the highest LEP concentration treatment at 0.25 mg/mL led to significant 
reduction in the percentage of stained cells, mean fluorescence intensity and 
median fluorescence intensity by 40.8%, 31.4% and 45.4%, respectively. On the 
other hand, hydrolyzed LEP at 0.25 mg/mL only reduced the percentage of 
stained cells and mean fluorescence intensity by 19.5% and 33.9%, respectively. 
The observations from flow cytometry are in agreement with the fluorescence 
microscopy and fluorescence spectrophotometry experiments. Representative 
histograms for all treatments are also shown in Fig. 4.5. The right shift from the 
treatment of LPS alone to the LPS + ATP treatment indicating the increased 
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fluorescence was counteracted by addition of 0.25 mg/mL LEP, both hydrolyzed 




Inflammation is linked to multiple diseases, such as in neurodegenerative 
disorders (Gao & Hong, 2008; Guo, Callaway, & Ting, 2015; Mao et al., 2017), 
type II diabetes (Strowig, Henao-Mejia, Elinav, & Flavell, 2012), inflammatory 
bowel disease (Peyrin-Biroulet, Lémann, 2011; Ruffolo et al., 2010), and cancer 
(Balkwill & Mantovani, 2001; Mantovani, Allavena, Sica, & Balkwill, 2008; Simone 
Reuter, 2011).  Inflammation, and complications associated with it, account for 
approximately 15% of cancer-related deaths (Mantovani et al., 2008).  If chronic 
inflammation can be inhibited without disruption of normal cell functions, this 
could lead to breakthroughs in possible treatments and preventative measures 
for these diseases.  One possible mechanism for inhibiting chronic inflammation 
is inhibiting the inflammasome, a multi-protein oligomer that is responsible for the 
production of pro-inflammatory cytokines, and only activated under specific 
conditions (Abais et al., 2015; Martinon, Burns, & Tschopp, 2002). 
     Lunasin has been reported to have anti-cancer and anti-inflammatory 
properties (Hernández-Ledesma et al., 2009; Hsieh et al., 2017), and ROSs have 
been linked to activation of the inflammasome (Abais et al., 2015; Guo et al., 
2015), but to our knowledge no studies have been done to determine if lunasin 
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can inhibit the inflammasome by reduction of ROSs within the cell.  This study 
used lunasin-enriched preparation that was obtained by calcium chloride 
precipitation (Price et al., 2016) to study its effect on inflammasome activation in 
vitro using THP-1 human macrophages as well as LPS and ATP signals, known 
initiators of inflammasome activation (Tschopp & Schroder, 2010).  
Inflammasomes require a two-step process in order to activate, first is priming 
with LPS which acts as an upstream regulator of NF-κB which transcribes pro-IL-
1β and NLRP3 (Ghonime et al., 2014), and then activation with ATP, which 
releases ROS within the cell, which is critical for the binding sites of the NLRP3 
to form a disulfide bond allowing oligomerization with ASC and pro-caspase-1 to 
form the inflammasome (Abais et al., 2015; Bae & Park, 2011).  ROSs have also 
been shown to be crucial in the activation of active caspase-1 by oxidizing 
thioredoxin (TRX), a redox protein, releasing thioredoxin-interacting protein 
(TXNIP) which binds to the NLRP3 portion of the inflammasome and has been 
proven to be a key step in activation (Abais et al., 2015; Zhou, Tardivel, Thorens, 
Choi, & Tschopp, 2010).  One of the most detrimental effects of this immune 
response is the cascade of pro-inflammatory cytokines, which act as the priming 
step like LPS, and the resulting cell and tissue death associated with sterile 
inflammation (Rock, Latz, Ontiveros, & Kono, 2010).  Cells treated with LEP 
showed significant reduction in pro-inflammatory cytokine production expressed 
into the supernatant, indicating there was an effect on the inflammasome 
pathway, leading us to study the mechanism of action involved.  Since there was 
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a reduction in cytokine expression, but NLRP3 and ASC were not affected by 
LEP indicating a different mechanism of action.Our study showed the effect of 
LEP in the production of intracellular ROS (Fig. 4.4 and 4.5) which could 
potentially explain the observed reduction in the production of pro-inflammatory 
cytokines IL-1β and IL-18 (Fig. 4.2). Previous studies have shown the ability of 
lunasin to act as antioxidant leading to reduced inflammation(Hernández-
Ledesma, Hsieh, & de Lumen, 2009). In addition, lunasin prevented galactose-
induced cataract formation in rats by attenuating oxidative damage through 
upregulation of antioxidant enzymes (Dai et al,, 2016) and protected DNA by 
suppressing generation of hydroxyl radical via blockage of the Fenton reaction 
(Jeong, de Lumen & Jeong, 2010). Our current study supported these previous 
studies showing the ability of LEP to reduce intracellular ROSs in THP-1 human 
macrophages involved in inflammasome activation. 
We also observed that pepsin-pancreatin hydrolysis led to lower ability of 
LEP to reduce intracellular ROS in THP-1 human macrophages treated with LPS 
and ATP. This may be attributed to reduction in amount of bioactive peptides 
present in hydrolyzed LEP as our previous study showed reduction in the 
concentrations of lunasin, Bowman-Birk inhibitor and Kunitz-type trypsin inhibitor 
after pepsin-pancreatin hydrolysis (Price, Pangloli, Krishnan, & Dia, 2016). In the 
previous study, more intact lunasin was associated with higher anti-proliferative 
effects in colon cancer cells (Cruz-Huerta et al., 2015) and addition of BBI 
complemented the anticancer effect of lunasin in xenograft model of breast 
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cancer (Hsieh, Hernandez-Ledesma, Jeong, Park & de Lumen, 2010). This 
indicated the importance of protecting lunasin from digestion to exert its potential 
chemoprevetive effect. Fig. 4.6 shows the proposed mechanism that lunasin 
uses to inhibit the production of pro-inflammatory cytokines IL-1ß and IL-18.  
Since lunasin was able to reduce cytokine expression and intracellular ROSs, but 
not inflammasome associated proteins, the two proposed mechanisms are 
blocking ROSs from activating the inflammasome, and inhibiting activation of the 
pro-interleukins. 
In conclusion, lunasin-enriched products are able to inhibit inflammasome 
activation in THP-1 human macrophages by reducing intracellular ROS,indicating 
its potential use in aiding relief of chronic inflammation. Since the NLRP3 and 
ASC proteins were not affected by LEP treatment in LPS+ATP inflammasome-
activated THP-1 human macrophages, further studies are needed to determine 
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Fig. 4.1. Protein profile of lunasin-enriched material prepared by calcium 
chloride precipitation methods.  Figure 4.1a shows size-exclusion 
chromatography of CaCl2 lunasin-enriched product, chromatogram overlays 
hydrolyzed (blue) and unhydrolyzed (red) samples.  Unhydrolyzed sample 
contains large peak associated with high molecular weight compounds which 
were reduced after pepsin-pancreatin hydrolysis. Figure 4.1b shows high-
performance liquid chromatography results of hydrolyzed sample (red), 
unhydrolyzed (green), and lunasin standard (blue).  Results show a reduction of 












































*DAD1 A, Sig=295,100 Ref=off (VERMONT\02212017_LUNA-SPL 2017-02-21 15-50-20\004-0401.D)
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Fig. 4.2. Lunasin-enriched preparation reduced the production of IL-1β and 
IL-18 in THP-1 human macrophages treated with LPS and ATP for 
inflammasome activation.  Figure 4.2a shows an overall reduction of IL-1β 
expression in LEP treated cells compared to the positive control of the LPS + 
ATP treated cells. Bars with different letter(s) are significantly different from each 
other (P<0.05).  Figure 4.2b shows the reduction in IL-18 secretion by THP-1 
human macrophages when treated with LEP. Bars with different letters were 







































































































LPS (1 µg/mL)   -                  +               +                +                +                + 
ATP (5 mM)       -                  -                +                +                +                + 
LPS (1 µg/mL)      -                  +                  +                +                   +                   + 
ATP (5 mM)          -                  -                   +                +                   +                   + 
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a)      b) 
Unhydrolyzed    Hydrolyzed 
ASC(25 kDa) ASC(25 kDa)  
 NLRP3(110 kDa)  NLRP3(110 kDa) 
 Actin (41 kDa)  Actin (41 kDa) 
  0       0         0   0.0625 0.125  0.25  Lunasin (mg/mL            0        0       0    0.0625 0.125  0.25 Lunasin (mg/mL) 
-  +         +       +        +        +      LPS (1 µg/mL)               -         +       +         +        +       +    LPS (1 µg/mL) 
-  -          +       +        +        +      ATP (5 mM)    -         +       +         +        +       +    ATP (5 mM)         
 
Fig. 4.3. Lunasin-enriched preparation did not affect the expression of 
NLRP3 and ASC proteins involved in the formation of inflammasome 






























Fig. 4.4. Lunasin-enriched preparation reduced production of intracellular 
reactive oxygen species as measured by fluorescence microscopy. 
Unhydrolyzed LEP (a) is more effective in lowering ROS production than 







































Fig. 4.4. continued 






Fig. 4.5. Measurement of intracellular ROS in THP-1 macrophages by 
fluorescence spectroscopy and flow cytometry shows that lunasin-
enriched treatment reduced intracellular reactive oxygen species 
production in THP-1 human macrophages treated with LPS and ATP.  a) 
Mean values of fluorescence spectroscopy indicate intracellular ROS was 
produced after treatment with LPS and ATP, with all values differing significantly 
from the negative control.  The highest concentration of hydrolyzed and 
unhydrolyzed LEP treatment (0.25mg) differ significantly from LPS + ATP 
treatment.  The three concentrations of unhydrolyzed LEP differ significantly from 
both LPS and LPS + ATP treatment, but the two lower concentrations of 
hydrolyzed LEP did not significantly reduce ROS compared to the LPS and LPS 
+ ATP treatments. b) Mean and median fluorescence intensity of flow cytometry 
compared with percentage of cells that were stained.  Highest concentration of 
hydrolyzed and unhydrolyzed LEP treated cells differ significantly from LPS and 
LPS + ATP treated cells.  Flow cytometry histogram shows a decrease in FITC-A 
corresponding to LEP treatment concentrations. Means with different letter(s) are 
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____ : LPS + ATP + 0.125 mg/mL lunasin-treated cells 
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Fig. 4.6. Proposed mechanism by which lunasin-enriched preparation (LEP) 
inhibit activation of inflammasomes in THP-1 human macrophages by LPS 
and ATP. Treatment of LPS and ATP lead to increase production of intracellular 
reactive oxygen species (ROS) which is capable of promoting oligomerization of 
NLRP3 and ASC components of inflammasome. This oligomer will then bind to 
pro-caspase-1 resulting in processing and activation of pro-caspase-1 to 
caspase-1. Active caspase-1 is responsible for the maturation of pro-
inflammatory cytokines IL-1β and IL-18 which are responsible for chronic 
inflammation. LEP treatment (      ) led to reduced production of these pro-
inflammatory cytokines by reducing the amount of intracellular ROS induced by 











































Production of lunasin-enriched materials was accomplished by both calcium 
chloride and pH precipitation methods. Bowman-Birk and Kunitz-Trypsin inhibitor 
played an important role in stabilizing lunasin against pepsin-pancreatin 
hydrolysis, and the use of KTI-mutant soybean study proved that KTI played a 
critical role in the stabilization of lunasin.  Treatment of THP-1 human 
macrophagesprimed and activated by LPS and ATP for inflammasome activation 
with lunasin-enriched material led to reduction of intracellular reactive oxygen 
species which resulted in reduced pro-inflammatory cytokines. This research is 
the first to report the following: 
• Importance of Kunitz trypsin inhibitor in the stability of lunasin against 
pepsin-pancreatin hydrolysis; and 
• Ability of lunasin-enriched material to inhibit activation of 
inflammasomes in vitro 
Determination of the exact component present in lunasin-enriched material 
responsible for the inhibition of inflammasomes is warranted. In addition, other 
mechanism of action involved in the inhibition of the inflammasomes must be 
studied. An in vivo study would be beneficial in determining if lunasin has the 







Samuel James Price attended Pellissippi State Community College (Knoxville, 
TN) for Hospitality Business and Culinary Arts from Fall of 2009 to Spring of 
2012.  After that, he attended the University of Tennessee where he obtained a 
Bachelor of Science degree in Food Science in Spring 2015.  He continued to 
pursue a Master of Science degree in Food Chemistry from the Fall of 2015 to 
the Spring of 2017.  While pursuing his M.S degree, he published his research in 
Food Research International.  While pursuing his B.S degree, he became a 
member of FarmHouse Fraternity, where he held multiple chairs and leadership 
positions.  He has worked in various positions while obtaining his degrees, at 
places such as Husk Nashville, House of Thaller, and The Irish Times. 
